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ABSTRACT 
ENGLISH 
Objective. Behavioural and psychological symptoms in dementia (BPSD) are 
common and are often treated with antipsychotics. Efficacy seems to be low and side 
effects are considerable. One potential side-effect might be cognitive decline. 
Further, there has however not been made an attempt to distinguish first and second 
generation antipsychotics in terms of efficacy and tolerability in these patients so far. 
Method. The databases PsiTri, Medline, Scopus, Embase, EBMR and 
www.ClincalStudyResults.org were searched for randomized, placebo-controlled 
trials using antipsychotics for treating BPSD and evaluated cognitive decline, 
efficacy, effectiveness and tolerability. Their results were summarized in a 
comprehensive meta-analysis. 
Results. After application of exclusion criteria, 29 studies were eligible for inclusion to 
the meta-analysis, ten of whom provided also data on cognitive functioning. 
Following pooled meta-analytic efficacy calculations both, conventional and atypical 
antipsychotics proved to be effective in treating BPSD as compared to placebo; 
effect-sizes, however, were very low; first generation antipsychotics showed a 
somewhat higher, yet still low effect-size. In terms of effectiveness and tolerability no 
difference was found. Treatment with antipsychotics as compared to placebo may 
lead to cognitive decline. 
Conclusions. Despite widespread clinical use the efficacy of antipsychotics in treating 
BPSD is low and is accompanied by considerable side-effects. Following 
randomised, controlled trials, the benefit-risk ratio is low with no relevant difference 
between first and second generation antipsychotics. 
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GERMAN 
Fragestellung. Verhaltensstörungen und psychische Störungen bei 
Demenzerkrankung sind häufig und werden oftmals mit Antipsychotika behandelt. 
Deren Wirksamkeit scheint gering zu sein, wobei Nebenwirkungen beträchtlich sind. 
Eine mögliche Nebenwirkung könnte die Abnahme der kognitiven Leistungsfähigkeit 
sein. Darüber hinaus wurden Antipsychotika der ersten und zweiten Generation 
hinsichtlich deren Wirksamkeit und Verträglichkeit bisher nicht  differenziert.  
Methoden. Die Datenbanken PsiTri, Medline, Scopus, Embase, EBMR und 
www.ClinicalStudyResults.org wurden nach randomisierten, Placebo-kontrollierten 
Studien durchsucht, in denen BPSD mit Antipsychotika therapiert wurde. Es wurden 
kognitiver Verfall, Wirksamkeit, Effektivität und Verträglichkeit ausgewertet. Deren 
Ergebnisse wurden in einer zusammenfassenden Meta-Analyse berechnet. 
Ergebnisse. Nach Anwendung der Ausschlusskriterien konnten 29 Studien in die 
Meta-Analyse eingeschlossen werden, von denen zehn Studien Daten zur kognitiven 
Funktion lieferten. Nach den zusammengefassten meta-analytischen Berechnungen 
stellten sich beide, konventionelle und atypische  Antipsychotika, im Vergleich zu 
Placebo als wirksam heraus. Die Effektstärke war sehr gering. Antipsychotika der 
ersten Generation zeigten einen etwas höhere Effektstärke, die aber immer noch als 
niedrig zu bewerten ist. Hinsichtlich Effektivität und Verträglichkeit fand sich kein 
Unterschied. Die Behandlung mit Antipsychotika könnte im Vergleich zu Placebo zu 
einer Abnahme der Kognition führen.  
Folgerung. Trotz weit verbreiteter klinischer Anwendung ist die Wirksamkeit von 
Antipsychotika bei der Behandlung von BPSD gering und von nennenswerten 
Nebenwirkungen begleitet. Aus den randomisierten, kontrollierten Studien geht ein 
geringes Nutzen-Risiko-Verhältnis hervor, bei dem es keine relevanten Unterschiede 
zwischen Antipsychotika der ersten und zweiten Generation gibt. 
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INTRODUCTION 
 
Behavioural and psychological symptoms of dementia (BPSD) affect nearly all 
patients suffering from dementia [1]. Neil found that BPSD were present in 96.2% in 
their collective of demented patients [2]. The most severe symptoms caregivers and 
physicians have to cope with, are depression, anxiety, sleeplessness, hallucinations, 
delusions, misidentifications, physical aggression, restlessness and wandering [3].  
Thus, treatment of BPSD faces more than one problem: the pathology of the patient 
and the burden to the caregivers with all their consequences. Matsumoto found that 
“the burden associated with BPSD is different for each symptom and does not always 
depend on frequency and severity of BPSD”. These findings suggest that some 
symptoms, such as agitation, aggression, irritability or lability may affect the 
caregivers significantly, although their frequency and severity are low [4]. There is still 
no efficient treatment strategy with convincing evidence for patients suffering from 
BPSD, neither with behavioural nor pharmacological approaches. Concerning 
pharmacological treatment there is no sufficient evidence for the use of 
antidepressants, mood-stabilisers or benzodiazepines. Anti-dementive agents such 
as choline-esterase inhibitors or memantine may have an effect on BPSD in certain 
subgroups. In clinical practice, antipsychotics are most commonly used for the 
treatment of these symptoms. Some meta-analyses have been conducted previously 
to evaluate their efficacy. Efficacy of antipsychotic treatment, despite being 
significant, seems to be of very low effect size [5, 6] and side-effects are 
considerable [7-11]. In the light of the controversial discussion on the benefits of 
second generation antipsychotics (SGA) over first generation antipsychotics (FGA) in 
patients with schizophrenia or bipolar disorder it also seems necessary to look at 
potential differences between these two groups in patients with dementia.  
Furthermore, some few studies indicate that the use of antipsychotic medication may 
have malevolent effects on cognitive functioning. In a two year prospective, 
longitudinal study it was found that patients with dementia taking antipsychotics had 
a cognitive decline twice as fast as patients who did not one year after first 
prescription [12]. A significant cognitive decline subsequent to the use of 
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antipsychotics for treating BPSD in patients with dementia would seriously limit their 
use. Taking into account that the efficacy of antipsychotics for BPSD is doubtful, the 
cost-effectiveness ratio of antipsychotics in patients with dementia would need to be 
reassessed. 
Therefore, the aim of this review and meta-analysis was to elucidate whether the use 
of antipsychotics in patients with dementia goes along with accelerated cognitive 
decline and to update the data on efficacy and tolerability of antipsychotics with the 
recently published studies (e.g. CATIE-AD) and to compare efficacy, effectiveness 
and tolerability of SGA versus FGA. 
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METHODS 
DATA ACQUISITION 
All published and unpublished randomized controlled trials that assessed the efficacy 
and tolerability of antipsychotics in the treatment of BPSD were searched for in PsiTri 
(http://psitri.stakes.fi). PSITRI is a register of controlled trials that compiles the 
registers of all Cochrane review groups in the field of mental health. The registers of 
the single Cochrane review groups are compiled by regular searches of numerous 
electronic databases and conference abstract books and hand searching of major 
journals (the exact search strategies of the individual review groups are listed in the 
Cochrane Library). Furthermore MEDLINE, EMBASE, SCOPUS and EBMR (last 
update: December 2008) were searched.  
The abstracts, titles, and index terms of studies were searched using the following 
key words: antipsychotic, antipsychotics, neuroleptic, neuroleptics, haloperidol, 
quetiapine, risperidone, aripiprazole, clozapine, olanzapine, zuclopenthixole, 
chlorpromazine, thioridazine, flupenthixol, sulpiride, melperone, pipamperone, 
pimozide and ziprasidone in conjunction with dementia, Alzheimer, Alzheimer’s, AD, 
vascular dementia, BPSD, behavioural and psychological, Pick, Pick’s Disease. 
ClinicalStudyResults (http://ClinicalStudyResults.org), an open database for trials, 
was also searched for diagnosis dementia or Alzheimer dementia in conjunction with 
quetiapine, risperidone, aripiprazole and olanzapine (last update: December 2008).  
In addition, the reference sections of included articles and key reviews were 
screened, and the first or last authors of the included studies and pharmaceutical 
companies (AstraZeneca, EliLilly, Janssen-Cilag, Bristol-Myers Squib, Pfizer) were 
asked by e-mail between December 2005 and October 2007 whether they were 
aware of further trials. They were also contacted for the provision of missing data 
necessary for the meta-analysis. We are grateful to Herz et al., DeVane et al., 
Luggen et al., Schneider et al., Nygaard et al. and Kasckow et al. for sending us 
additional data. In case clinical study reports (CSR) and published papers of the 
same study were both available, we referenced the CSR because it usually included 
  
   Methods 
 
6 
 
more data for evaluation. Two raters (F.G.P. and A.W.) independently screened the 
identified references. 
A rating based on the 3 quality categories described in the Cochrane Collaboration 
Handbook was given for each trial; A: low risk of bias (adequate allocation 
concealment), B: moderate risk of bias (some doubt about the results, mainly studies 
said to be randomised, but without an explanation of the method), and C: high risk of 
bias (clearly inadequate allocation concealment, e.g. alternate randomisation) [13]. 
The inclusion criterion for this review was a low or moderate risk of bias (category A 
or B, respectively). 
All papers were rated and data extracted independently by F.G.P. and A.W. onto 
standard simple forms. Any disagreement was discussed with a third reviewer (S.L.), 
and decisions were documented. If necessary, authors of studies were contacted for 
clarification. 
Inclusion criteria were at least single-blinded, randomized, controlled trials with 
minimum duration of one week which provide the data in one or more of the following 
categories: 
1. Efficacy for behavioural symptoms: Mean Endpoint or Mean Change in at least 
one of the following scales (in order of importance):  
• Cohen Mansfield Agitation Inventory (CMAI)  
• Neuropsychiatric Inventory (NPI) 
• Brief Psychiatric Rating Scale (BPRS)  
• Behavioural pathology in Alzheimer’s disease Rating Scale (BEHAVE AD) 
• Agitation Analog Scale 
• Neurobehavioral Rating Scale 
2. Acceptability of treatment and effectiveness:  
• Drop-Out rate overall 
• Drop-Outs due to Adverse Events (DOAE) 
• Drop-Outs due to Inefficacy (DOI) 
3. Tolerability: Data on occurring of  
• extrapyramidal symptoms (EPS)  
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• death 
• serious adverse events (SAE) 
• somnolence 
• agitation 
• accidental injury 
• akathisia 
• dyskinesia  
• parkinsonoid 
4. Cognition: Mean Endpoint or Mean Change in cognitive scales; only the Mini 
Mental State Examination (MMSE) was applied in all studies investigating 
cognitive functioning. 
 
OUTCOME PARAMETERS 
The primary outcome of interest was the mean change in efficacy as rated with the 
above named instruments from baseline to endpoint. Further outcome parameters 
were the rate of response and acceptability/effectiveness criteria such as the number 
of participants leaving the study early (Drop-Outs) for any reason, DOAE, DOI and 
tolerability issues including cognitive decline. 
 In a ‘once randomized – analyzed’ approach (Last Observed Carrier Forward 
method) we assumed in the case of dichotomous data that participants who dropped 
out prior to completion had no change in their condition unless otherwise stated. 
Continuous data had to be reported as presented in the original studies without any 
assumptions about those lost to follow-up, but intent-to-treat results were used 
whenever presented. 
 
META-ANALYTIC CALCULATIONS 
The outcome data were combined in a meta-analysis. The standardized mean 
differences (SMD) based on Hedges’s adjusted g (a slightly modified version of the 
Cohen’s D for correction in the case of small participant numbers below 10) was 
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calculated [14] and their 95% confidence interval (CI) as effect size measures. When 
standard deviations were not indicated, they were either derived from P values or the 
mean standard deviations of the other studies was used. 
For dichotomous data, the relative risk (RR) along with its 95% confidence interval 
(CI) was estimated. The RR is defined as the ratio of the risk of an unfavourable 
outcome among treatment-allocated participants to the corresponding risk of an 
unfavourable outcome among those in the control group.  
Whereas many meta-analysts preferred to use odds ratios some years ago, it has 
been shown that the RR is more intuitive [15] and that odds ratios tend to be 
interpreted as RR by clinicians [16]. This misinterpretation then leads to an 
overestimated impression of the effect. We also present absolute risk differences and 
numbers-needed-to-treat/harm calculated as the inverse of the absolute difference. 
There are disadvantages of both fixed and random effects models. The random 
effects model takes heterogeneity among studies into account, even if this 
heterogeneity is not statistically significant, but gives more weight to smaller studies 
which are often most prone to bias. Therefore, results based on both the random 
effects model (primary model) and the fixed effects model are presented [17]. Study 
heterogeneity was assessed by a chi-square test and the I-square statistic [18]. The 
chi-square test contrasts the effect sizes of the individual trials with the pooled effect 
size. Significance levels of p < 0.1 were set a priori in order to assume the presence 
of heterogeneity. The I-square statistic provides an estimate of the percentage of 
variability due to heterogeneity rather than chance alone. We interpreted values 
≥ 50% as considerable heterogeneity [18]. When the results were statistically 
significantly heterogeneous, reasons for the heterogeneity were sought for by re-
reading the publications. 
Studies with negative results are less likely to be published than studies with 
significant results. The possibility of such publication bias was examined using the 
“funnel plot” method described by Egger and colleagues [19]. 
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All calculations were performed using Comprehensive Meta-analysis version 2. The 
exact formulas are reported there [20]. P < 0,05 was considered statistically 
significant. 
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RESULTS 
INCLUDED STUDIES 
The search yielded 376 publications. 100 studies were more closely inspected of 
which 71 were excluded for the reasons specified in figure 1. 29 trials with 37 active 
comparator arms and 6.482 participants (antipsychotics: 4.288; placebo: 2.194) were 
included and of these 26 provided data on either efficacy [21-46] 26 on effectiveness 
[21-33, 35-42, 44, 46-49], 19 on tolerability [22-24, 26-33, 37, 39, 40, 42, 44, 46, 47, 
49], and 10 on cognitive functioning [21-24, 31, 42-46] (see table 1, for further details 
see table 2). Studies with the following drugs were identified: aripiprazole, 
olanzapine, quetiapine, risperidone (SGA), and haloperidol, loxapine, perphenazine, 
pimozide, thioridazine, thiothixene, tiapride (FGA). 
All but three studies were short-term and lasted 12 weeks or less. Therefore, these 
results were used in the primary analysis. We assessed in a sensitivity analysis 
whether the results changed when long-term (26 weeks) instead of short-term results 
were used [24, 26], and one 16 weeks study was added [45]. In the tolerability and 
the effectiveness analysis we only used data from long-term assessment. In the 
cognitive analysis all but two studies were short-term and lasted 12 weeks or less. 
Therefore, these results were used in the primary analysis. We assessed in a 
sensitivity analysis whether the results changed when long-terms (26 weeks) instead 
of short-term results were used [24], and one 16 weeks study was added [45]. 
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FIGURE 1: SELECTION OF STUDIES TO BE INCLUDED IN META-ANALYTIC CALCULATION 
 
TABLE 1: TOTAL NUMBER OF PATIENTS OF INCLUDED TRIALS FOR EFFICACY, 
ACCEPTABILITY/EFFECTIVENESS AND TOLERABILITY ANALYSIS 
Study participants in the treatment 
arm with the following agent 
N Antipsychotic N Placebo N trials 
Aripiprazole 597 354 3 
Olanzapine 1.288 628 7 
Quetiapine 477 384 5 
Risperidone 1.288 948 8 
SGA 3.650 1.928  
Haloperidol 414 402 7 
Loxapine 38 39 2 
Perphenazine 33 21 1 
Pimozide 18 23 1 
Thioridazine 17 17 1 
Thiothixene 16 16 1 
Tiapride 102 103 1 
FGA 638 479  
    
Overall 4.288 2.194  
The number of patients receiving placebo in the SGA and FGA comparisons does not add up to the overall number because of 
multiple arms in some studies. 
100 studies found
29 randomized 
placebo-controlled trials 
44 studies excluded because 
of inappropriate study design
(not placebo-controlled, post-hoc analysis,
single blind, open label, etc.) 
17 studies excluded because 
of other diagnosis
or treatment procedures
1 study excluded because 
of length less than one week
26 studies in 
Efficacy analysis
19 studies in 
Tolerability analysis
26 studies in 
Effectiveness analysis
9 studies excluded because 
of missing or incompatible 
data
10 studies in 
Cognition analysis
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CN138005 
2004 Aripirazole 
2-15 AD 
13,26 
10 
N / A 
76 CMAI     x  x     x x 
125 126 N / A 
 Placebo 13,94 N / A 131 121 N / A 
Breder 
2004 Aripirazole 
2-10 AD 12.4 (4.4) 10 82.5 79 CMAI    x x x  x x x x x  
366 347 N / A 
 Placebo 121 115 N / A 
De Deyn 
2005 Aripirazole 
2-15 AD 
14,13 
10 81,5 72 NPI    x x  x   x x x x 
106 103 83 
 Placebo 14,35 102 100 82 
Herz 
unpublishe
d 
Olanzapine 
2,5-20 AD 
N / A 
6 
N / A N / A 
Agita-tion 
Analog          x x x  
7 4 
N / A 
 Placebo N / A N / A N / A 8 8 
N / A 
F1D-MC-
HGAO 
2005 
Olanzapine 
1-8 AD 
11,08 
(7,33) 
8 
78,24 
(6,91) 65,8 
BEHAVE AD  x x   x  x  x x x x 
120 100 51,7 
 Placebo 10,25 (6,30) 
78,93 
(6,3) 66,9 118 105 51,7 
Street 2000 Olanzapine  
5-15 AD 
6,8 
(6,6) 
6 
83,15 
(6,57) 61,0 
NPI  x x  x x x x x x x x x 
159 156 73,0 
 Placebo 7,3 (6,3) 
81,4 
(6,7) 61,7 47 44 76,6 
Deberdt 
2005  Olanzapine  2,5-10 
(5,2) 
AD, VD, 
mixed 
14,0 
(5,4) 
12 
77,9 
(7,7) 69,1 
NPI  x x  x x  x x x  x  
204 193 62,3 
 Placebo 15,2 (6,2) 
79,8 
(7,2) 63,8 94 91 79,8 
F1D-MC-
HGIC 2005 Olanzapine  
2,5-5 AD 
21,49 
12 
77,57 
(8,03) 55,1 
NPI             x 
178 171 N / A 
* short term Placebo 21,47 77,72 (7,78) 57,8 90 88 N / A 
F1D-MC-
HGIC 2005 Olanzapine  
2,5-5 AD 
21,49 
26 
77,57 
(8,03) 55,1 
NPI x x x     x x x x x x 
178 171 60,1 
* long term Placebo 21,47 77,72 (7,78) 57,8 90 88 73,3 
De Deyn 
2004 Olanzapine  
1-7,5 AD 
N / A 
10 76,6 (10,4) 75 CGI x  x  x x x   x x x  
520 513 N / A 
F1D-MC-
HGIV Placebo N / A 129 129 N / A 
Sultzer 
2008 Olanzapine  
(5,5) NPI 
15,0 
(5,4) 
12 77,9 (7,5) 56 NPI             x 
100 99 20,0 
 Placebo 14,7 (5,8) 142 139 14,8 
Schneider 
2006 Olanzapine  
(5,5) AD 
15,0 
(5,4) 
12 
78,8 
(7,3) 55 
 x x x x x x x x x x x x  
100 40 20,0 
 Placebo 14,7 (5,8) 
77,3 
(7,1) 57 142 47 14,8 
Tariot 2006 Quetiapine 
(96,9) AD 
12,40 
(5,09) 
10 
81,92 
(6,85) 72,5 
BPRS     x x x x x x x x x 
91 85 68,1 
 Placebo 13,15 (5,44) 
83,93 
(6,66) 79,8 99 94 63,6 
Ballard 
2005 Quetiapine 
2 x 25-50 AD 
N / A 
6 
84,2 
(8,6) 87,1 
CMAI     x     x    
31 27 74 
* short term Placebo 
N / A 83,0 
(6,8) 77,4 31 29 96,8 
Ballard 
2005 Quetiapine 
2 x 50 AD 
N / A 
26 
84,2 
(8,6) 87,1 
CMAI              
31 27 N / A 
* long term Placebo 
N / A 83,0 
(6,8) 77,4 31 30 N / A 
Zhong 
2007 Quetiapine 
100-200 AD, VD  
5,2 
(3,8) 
10 
83,2 
(7,6) 75,5 
CMAI    x x  x x  x x x x 
241 234 64,3 
 Placebo 5,5 (4,0) 
83,2 
(7,2) 70,7 92 92 65,2 
Sultzer 
2008 Quetiapine 
(56,5) AD 
14,9 
(6,1) 
12 77,9 (7,5) 56 NPI             x 
94 94 18,1 
 Placebo 14,7 (5,8) 142 139 14,8 
Schneider 
2006 Quetiapine  
(56,5) AD 
14,9 
(6,1) 
12 
77,3 
(8,7) 53 
 x x x x x x x x x x x x  
94 31 18,1 
 Placebo 14,7 (5,8) 
77,3 
(7,1) 57 142 47 14,8 
Paleacu 
2007 Quetiapine  
25-300 AD 
14,5 
(6,3) 
6 82,2 (6,4) 65   x x       x x x  
20 20 60 
 Placebo 14,3 (6,8) 20 20 75 
Herz 
unpublishe
d 
Risperidone 
0,5 – 4 AD 
N / A 
6 
N / A N / A 
Agitation 
Analog          x x x  
14 13 N / A 
 Placebo N / A 
N / A N / A 
8 8 N / A 
Brodaty 
2003 Risperidone 
(0,95) AD, VD, mixed 
5,14 
(SE 
0,45) 12 
83,2 
(SE 
0,51) 
71,2 
BEHAVE AD    x x x x x x x x x   
167 149 73,1 
 Placebo 
5,78 
(SE 
0,46) 
82,7 
(SE 
0,64) 
72,4 170 152 67,1 
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De Deyn 
1999 Risperidone 
(1,1) AD, VD, mixed 
8,6 
12 
medi
an 81 56,5 
BEHAVE AD        x  x    
115 115 59,1 
 Placebo  8,8 
medi
an 81 58,8 114 114 64,9 
Katz 1999 Risperidone 
0,5-2 AD, VD, mixed 
6,6 
(6,3) 12 
82,7 
(7,7) 67,8 BEHAVE AD    x x x x x x x x x  
456 456 68,4 
 Placebo 163 161 73,0 
Mintzer 
2006 Risperidone 
1-1,5 AD 
13,2 
(4,93) 
8 
83,4 
(7,20) 77,9 
BEHAVE AD     x x x x x x x x  
235 201 75 
 Placebo 13,2 (5,01) 
83,2 
(7,38) 76,1 238 212 75 
RIS-BEL 14 
2001 Risperidone 
1-4 AD 
9,8 
4 
79,0 65 
BEHAVE AD          x x x x 
20 20 80 
 Placebo 7,8 77,6 74 19 19 78,9 
Deberdt 
2005 Risperidone 0,5-2  
(1,0) 
AD, VD, 
mixed 
14,7 
(5,5) 
10 
78,0 
(6,9) 62,8 
NPI x x x  x x  x x   x  
196 190 68,9 
 Placebo 15,2 (6,2) 
79,8 
(7,2) 63,8 94 91 79,8 
Sultzer 
2008 Risperidone 
(1,0) NPI 
15,7 
(6,1) 
12 77,9 (7,5) 56 NPI             x 
85 84 22,4 
 Placebo 14,7 (5,8) 142 139 14,8 
Schneider 
2006 Risperidone 
(1,0) AD 
15,7 
(6,1) 
12 
78,4 
(7,1) 58 
 x x x x x x x x x x x x  
85 32 22,4 
 Placebo 14,7 (5,8) 
77,3 
(7,1) 57 142 47 14,8 
De Deyn 
1999 Haloperidol 
1,2 AD, VD, mixed 
7,9 
12 
medi
an 82 53,9 
BEHAVE AD        x  x    
115 115 70,4 
 Placebo 8,8 median 81 58,8 114 114 64,9 
Devanand 
1998 Haloperidol 
0,5-3 AD 19,4 (11,6) 6 
72,1 
(9,6) 64,8 BPRS              
44 40 90,9 
 Placebo 22 20 90,9 
Petrie 1982 Haloperidol 
4,6     
(0,3) 
prim/sec 
degen. 
Dement., 
VD 
N / A 
8 
72,1 
(5,3) 60 
BPRS    x      x x   
20 20 60,0 
 Placebo N / A 72,5 (8,9) 55,5 22 22 59,1 
Tariot 2006 Haloperidol 
(1,9) AD 
12,73 
(5,60) 
10 
83,55 
(6,05) 67,0 
BPRS     x x x x x x x x  
94 86 58,5 
 Placebo 13,15 (5,44) 
83,93 
(6,66) 79,8 99 94 63,6 
Auchus 
1997 Haloperidol 
3 AD 15,2 (4,6) 6 
75,6 
(7,5) N / A CMAI          x  x  
6 6 N / A 
 Placebo 6 6 N / A 
Allain 2000 Haloperidol 
(3,53) AD, VD, mixed 
N / A 
3 
79,9 
(7,9) 62 
    x x   x  x x x  
101 N / A N / A 
 Placebo N / A 78,6 (7,3) 69 103 N / A N / A 
Teri 2000 Haloperidol 
0,5-3 AD 
13 (8) 
16 
75,3 
(6,9) 59 
CMAI             x 
34 34 58,8 
 Placebo 13 (8) 75,8 (6,2) 67 36 36 69,4 
Barnes 
1982 Loxapine 
10,5 Dement. 
N / A 
8 
N / A N / A 
BPRS    x      x  x  
19 19 68,4 
 Placebo N / A N / A N / A 17 17 58,8 
Petrie 1982  Loxapine 
21,9  
(1,6) 
prim/sec 
degen. 
Dement., 
VD 
N / A 
8 
73,5 
(6,7) 36,8 
BPRS    x      x x   
19 19 63,2 
 Placebo N / A 72,5 (8,9) 55,5 22 22 59,1 
Pollock 
2002 
Perphe-
nazine 6,5  
(1,7) 
AD, VD, 
mixed, 
LB 
6,4 
(6,4) 
Up 
to 
17 
day
s 
80,4 
(9,0) 72,7 
Neuro-
behavioral 
Rating  
Scale 
         x    
33 33 45 
 Placebo 6,4 (6,8) 
78,5 
(8,5) 57,1 21 21 43 
Kodijan 
1986 Pimozide Up to 12 
mg 
Senile 
Dement. 
N / A 
12 
73,3 6 
BPRS          x x x  
18 18 N/A 
 Placebo 
N / A 
81,1 9 23 23 N/A 
Barnes 
1982 
Thiori- 
dazine 
62,5 Dement. 
N / A 
8 
N / A N / A 
BPRS    x      x  x  
17 17 64,7 
 Placebo N / A N / A N / A 17 17 58,8 
Finkel 1995 Thiothixene 
0,25-18 Dement. 8,81 11 85 86 CMAI          x x x  
16 16 N / A 
 Placebo 16 16 N / A 
Allain 2000 Tiapride 
(175,45) AD, VD, mixed 
N / A 
3 
80,3 
(7,6) 62 
    x x   x  x x x  
102 N / A N / A 
 Placebo N / A 78,6 (7,3) 69 103 N / A N / A 
N rand = number of patients randomized, N LOCF = number of patients with Last Observation Carried Forwards, C = 
Completers, Dement. = Dementia, AD = Alzheimer Dementia, VD = Vascular Dementia, LB = Lewy Body Dementia, MMSE = 
Mini Mental State Examination, NPI = Neuropsychiatric Inventory, BPRS = Brief Psychiatric Rating Scale, CMAI = Cohen 
Mansfield Agitation Inventory  
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EFFICACY ANALYSIS 
26 trials with 34 arms and 6.136 participants (antipsychotics: 4.065; placebo: 2.071) 
provided data on efficacy and were included in the efficacy analysis [21-46], three did 
not provide data [47-49]. It is worth mentioning that the papers published by 
Schneider et al. [49] and Sultzer et al. [43] both show results from the CATIE-AD trial, 
but deliver different data (see table 1). Pooled analysis of all antipsychotics revealed 
no heterogeneity (Q value: 31,5; df(Q): 26; p = 0,21; I2: 17,6), therefore the fixed 
effects model is appropriate. Antipsychotics were generally more efficacious in 
treating BPSD than placebo, however effect-size was very low (Hedges’s g = -0,13, 
CI: -0,19 – -0,08; p < 0,00001). Effect size of FGA (n = 352) versus placebo (n = 333) 
was slightly higher (Hedges’s g = -0,24, CI: -0,39 – -0,09, p = 0,0002) than of SGA 
(n = 3.095) versus placebo (n = 1.813) (Hedges’s g = -0,12, CI: -0,18 – -0,06, 
p = 0,0017) (see figure 2). 
 
FIGURE 2: POOLED ANALYSES OF EFFICACY OF SECOND GENERATION ANTIPSYCHOTICS 
(SGA) AND FIRST GENERATION ANTIPSYCHOTICS (FGA)  
 
 
 
 
Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit
p-Value
All SGAs pooled Fixed Effects Analysis -0,12 -0,18 -0,06 0,00
All SGAs pooled Random Effects Analysis -0,12 -0,18 -0,05 0,00
All FGAs pooled Fixed Effects Analysis -0,24 -0,39 -0,09 0,00
All FGAs pooled Random Effects Analysis -0,24 -0,39 -0,09 0,00
-1,00 -0,50 0,00 0,50 1,00
Favours Antipsychotic Favours Placebo
Test for heterogeneity: Chi2=21,19, df=17.0, (p=0,22), I2=19,78 %
Test for heterogeneity: Chi2=8,06, df=8,0, (p=0,43), I2=0,70%
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In the pooled analysis of single drugs, test for heterogeneity was only significant for 
risperidone (Q value: 17,7; df(Q): 7,0; p = 0,01; I2: 60,5), therefore homogeneity of 
studies was assumed for all other drugs. Loxapine showed the highest effect size 
(Hedges’s g = -0,47, CI: -0,91 – -0,02, p = 0,04). Haloperidol also proved to be 
significantly efficacious (Hedges’s g = -0,24, CI: -0,41 – -0,07, p = 0,01), whereas all 
other investigated FGA (perphenazine, pimozide, thioridazine, thiothixene) did not. Of 
the SGA, aripiprazole was the only efficacious antipsychotic (Hedges’s g = -0,2, CI: -
0,34 – -0,06, p = 0,01). Due to heterogeneity the random effects model had to be 
applied for risperidone, this failed, however, to reach significance (p = 0,07) (see 
figure 3). In the sensitivity analysis with results of long-term study results were 
comparable (FGA: Hedges’s g = -0,22, CI: -0,37 – -0,08, p < 0,001; SGA: Hedges’s g 
= -0,11, CI: -0,17 – -0,05, p < 0,001). 
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FIGURE 3: EFFICACY ANALYSIS OF ALL ANTIPSYCHOTIC AGENTS
 
Study Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
CN138005 2004Aripiprazole -0,24 -0,49 0,00 0,05
Breder 2004 -0,24 -0,45 -0,03 0,03
De Deyn 2005 -0,08 -0,35 0,20 0,58
Aripiprazole pooled Fixed Effects Model -0,20 -0,34 -0,06 0,01
Aripirazole pooled Random Effects Model -0,20 -0,34 -0,06 0,01
Tariot 2006Haloperidol -0,04 -0,33 0,25 0,80
De Deyn 1999 -0,42 -0,68 -0,15 0,00
Devanand 1998 0,08 -0,45 0,61 0,77
Petrie 1982 -0,64 -1,25 -0,03 0,04
Auchus 1997 -0,05 -1,09 1,00 0,93
Haloperidol pooled Fixed Effects Model -0,24 -0,41 -0,07 0,01
Haloperidol pooled Random Effects Model -0,23 -0,48 0,03 0,08
Petrie 1982Loxapine -0,65 -1,27 -0,03 0,04
Barnes 1982 -0,26 -0,91 0,38 0,42
Loxapine pooled Fixed Effects Model -0,47 -0,91 -0,02 0,04
Loxapine pooled Random Effects Model -0,47 -0,91 -0,02 0,04
Herz unpublishedOlanzapine -0,43 -1,55 0,69 0,45
F1D-MC-HGAO 2005 -0,05 -0,32 0,23 0,74
Street 2000 -0,20 -0,54 0,13 0,23
Deberdt 2005 0,02 -0,23 0,27 0,86
F1D-MC-HGIC 2005 0,17 -0,09 0,42 0,21
DeDeyn 2004 -0,14 -0,34 0,05 0,15
Sultzer 2008 -0,15 -0,40 0,11 0,27
Olanzapine pooled Fixed Effects Model -0,06 -0,16 0,04 0,23
Olanzapine pooled Random Effects Model -0,06 -0,16 0,04 0,23
Pollock 2002 Perphenazine -0,41 -0,96 0,13 0,14
Perphenazine pooled Fixed Effects Model -0,41 -0,96 0,13 0,14
Perphenazine pooled Random Effects Model -0,41 -0,96 0,13 0,14
Kodijan 1986Pimozide -0,02 -0,62 0,59 0,95
Pimozide pooled Fixed Effects Model -0,02 -0,62 0,59 0,95
Pimozide pooled Random Effects Model -0,02 -0,62 0,59 0,95
Sultzer 2008Quetiapine -0,15 -0,42 0,11 0,25
Tariot 2006 -0,22 -0,51 0,07 0,14
Ballard 2005 0,13 -0,39 0,65 0,62
Zhong 2007 -0,06 -0,30 0,18 0,64
Quetiapine pooled Fixed Effects Model -0,11 -0,26 0,03 0,13
Quetiapine pooled Random Effects Model -0,11 -0,26 0,03 0,13
Herz unpublishedRisperidone -0,70 -1,57 0,18 0,12
Deberdt 2005 0,13 -0,12 0,38 0,32
Sultzer 2008 -0,40 -0,67 -0,13 0,00
Brodaty 2003 -0,39 -0,61 -0,16 0,00
De Deyn 1999 -0,17 -0,43 0,09 0,19
Katz 1999 -0,09 -0,27 0,09 0,33
Mintzer 2006 0,01 -0,18 0,20 0,90
RIS-BEL 14 2001 0,18 -0,44 0,80 0,57
Risperidone pooled Fixed Effects Model -0,13 -0,22 -0,04 0,00
Risperidone pooled Random Effects Model -0,14 -0,30 0,01 0,07
Barnes 1982Thioridazine -0,00 -0,66 0,66 1,00
Thioridazine pooled Fixed Effects Model -0,00 -0,66 0,66 1,00
Thioridazine pooled Random Effects Model -0,00 -0,66 0,66 1,00
Finkel 1995Thiothixene -0,41 -1,09 0,27 0,24
Thiothixene pooled Fixed Effects Model -0,41 -1,09 0,27 0,24
Thiothixene pooled Random effects Model -0,41 -1,09 0,27 0,24
-1,00 -0,50 0,00 0,50 1,00
Favours Antipsychotic Favours Placebo
Antipsychotic
Test for heterogeneity:
Aripiprazole: Chi2=1,02, df=2,00, (p=0,60), I2=0,00 % Pimozide: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 %
Haloperidol: Chi2=7,28, df=5,00, (p=0,20), I2=31,36 % Quetiapine: Chi2=1,25, df=3,00, (p=0,74), I2=0,00 %
Loxapine: Chi2=0,73, df=1,00, (p=0,39), I2=0,00 % Risperidone: Chi2=17,71, df=7,00, (p=0,01), I2=60,48 %
Olanzapine: Chi2=8,40, df=6,00, (p=0,21), I2=28,58 % Thioridazine: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 %
Perphenazine: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 % Thiothixene: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 %
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EFFECTIVENESS ANALYSIS 
In the effectiveness analysis results for the pooled analysis of all antipsychotics vs. 
placebo and both subgroups FGA and SGA vs. placebo were rather alike. The tests 
for heterogeneity indicated the fixed effects model to be appropriate for all pooled 
analyses of groups and single drugs. The global drop-out rates between active 
comparator drugs and placebo were comparable. DOI, however, were more frequent 
in the placebo groups whereas DOAE were significantly more prevalent in the active 
comparator group (see figure 4).  
The lowest global drop-out rates in relation to placebo were found for thiothixene, 
tiapride, and loxapine. Data on DAI were not available for perphenazine and 
thioridazine, on DOAE for perphenazine and thiothixene. For a detailed analysis of 
the individual drugs see table 3. 
FIGURE 4: POOLED ANALYSES OF EFFECTIVENESS CRITERIA DROP-OUT
 
Total: number of patients in analysis, FGA: First Generation Antipsychotic, SGA: Second generation 
Antipsychotic, DO: Drop Out, IE: Inefficacy, AE: Adverse Events 
Risk ratio and 95% CI
Risk Lower Upper 
ratio limit limit p-Value Total
DO global All pooled 1,005 0,937 1,079 0,883 5427
DO global FGA pooled 1,022 0,847 1,233 0,822 912
DO global SGA pooled 1,005 0,934 1,081 0,895 4936
DO IE All pooled 0,702 0,553 0,892 0,004 1830
DO IE FGA pooled 0,704 0,599 0,828 0,000 3349
DO IE SGA pooled 0,714 0,621 0,822 0,000 4347
0,01 0,1 1 10 100
DO AE All pooled 1,537 1,279 1,848 0,000 5148
DO AE FGA pooled 1,620 0,980 2,677 0,060 486
DO AE SGA pooled 1,494 1,235 1,808 0,000 4854
Favours Antipsychotic Favours Placebo
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TABLE 3: OVERVIEW AND RESULTS OF CLINICAL TRIALS INCLUDED IN THE EFFECTIVENESS 
ANALYSES 
Fixed = Fixed effects model, Random = Random Effects Model, RR = Risk ratio, Lower = Lower limit, 
Upper = Upper limit, Total = Total sample size 
  
Antipsychotic Study name Drop-Outs due to Adverse Events
RR Lower Upper p-Value Total RR Lower Upper p-Value Total RR Lower Upper p-Value Total 
Aripiprazole De Deyn 2005 0,96 0,53 1,74 0,90 208 1,37 0,54 3,47 0,50 208 0,48 0,12 1,87 0,29 208
Breder 2004 0,87 0,69 1,09 0,23 487 1,28 0,77 2,13 0,34 487 0,74 0,51 1,07 0,10 487
CN138005 2004 1,62 0,77 3,41 0,20 256
Fixed 0,88 0,71 1,09 0,24 695 1,38 0,94 2,02 0,10 951 0,71 0,50 1,02 0,07 695
Random 0,88 0,71 1,09 0,24 695 1,38 0,94 2,02 0,10 951 0,71 0,50 1,02 0,07 695
Haloperidol Tariot 2006 1,14 0,80 1,63 0,47 193 1,38 0,71 2,68 0,35 193 0,79 0,35 1,79 0,57 193
De Deyn 1999 0,84 0,58 1,23 0,37 229
Allain 2000 1,34 0,74 2,41 0,33 204 2,89 1,19 7,03 0,02 204 0,13 0,02 1,00 0,05 204
Auchus 1997 2,00 0,24 16,61 0,52 12 2,00 0,24 16,61 0,52 12
Petrie 1982 0,98 0,47 2,04 0,95 42 0,79 0,30 2,08 0,63 42
Teri 2000 1,35 0,71 2,54 0,36 70
Fixed 1,07 0,87 1,32 0,53 750 1,81 1,08 3,03 0,02 409 0,68 0,37 1,23 0,20 439
Random 1,07 0,87 1,32 0,53 750 1,81 1,08 3,03 0,02 409 0,63 0,30 1,34 0,23 439
Loxapine Petrie 1982 0,90 0,42 1,95 0,79 41 0,50 0,15 1,66 0,25 41
Barnes 1982 0,77 0,32 1,83 0,55 36 1,79 0,37 8,57 0,47 36
Fixed 0,84 0,47 1,50 0,55 77 1,79 0,37 8,57 0,47 36 0,50 0,15 1,66 0,25 41
Random 0,84 0,47 1,50 0,55 77 1,79 0,37 8,57 0,47 36 0,50 0,15 1,66 0,25 41
Olanzapine F1D-MC-HGAO 2005 1,00 0,77 1,30 1,00 238 1,11 0,44 2,77 0,83 238 0,94 0,66 1,33 0,71 238
Street 2000 1,16 0,65 2,06 0,62 206 2,81 0,68 11,62 0,15 206 0,49 0,12 1,99 0,32 206
Deberdt 2005 1,87 1,20 2,90 0,01 298 5,07 1,59 16,11 0,01 298
De Deyn 2004 0,95 0,71 1,29 0,75 649 3,42 1,41 8,31 0,01 649 0,50 0,32 0,77 0,00 649
Herz unpublished 3,43 0,45 25,93 0,23 15 3,37 0,16 71,67 0,44 15 7,88 0,48 130,28 0,15 15
Schneider 2006 0,94 0,83 1,06 0,30 242 4,87 2,18 10,86 0,00 242 0,57 0,44 0,75 0,00 242
F1D-MC-HGIC 2005 1,50 1,02 2,20 0,04 268 2,78 0,99 7,83 0,05 268 1,26 0,58 2,76 0,56 268
Fixed 1,02 0,92 1,12 0,75 1916 3,02 2,03 4,50 0,00 1916 0,67 0,56 0,81 0,00 1618
Random 1,14 0,93 1,40 0,20 1916 3,01 1,95 4,64 0,00 1916 0,73 0,50 1,04 0,08 1618
Perphenazine Pollock 2002 0,95 0,59 1,55 0,85 54
Fixed 0,95 0,59 1,55 0,85 54
Random 0,95 0,59 1,55 0,85 54
Pimozide Kodijan 1986 2,56 0,91 7,16 0,07 41 16,42 0,99 273,51 0,05 41 0,85 0,16 4,57 0,85 41
Fixed 2,56 0,91 7,16 0,07 41 16,42 0,99 273,51 0,05 41 0,85 0,16 4,57 0,85 41
Random 2,56 0,91 7,16 0,07 41 16,42 0,99 273,51 0,05 41 0,85 0,16 4,57 0,85 41
Quetiapine Tariot 2006 0,88 0,59 1,30 0,52 190 0,84 0,39 1,81 0,65 190 0,73 0,31 1,69 0,46 190
Schneider 2006 0,96 0,86 1,08 0,51 236 3,24 1,37 7,64 0,01 236 0,78 0,62 0,97 0,03 236
Zhong 2007 1,03 0,74 1,42 0,88 333 1,15 0,56 2,34 0,71 333 0,73 0,37 1,45 0,37 333
Ballard 2005 8,00 1,06 60,21 0,04 62
Paleacu 2007 1,60 0,63 4,05 0,32 40 1,00 0,07 14,90 1,00 40 1,20 0,44 3,30 0,72 40
Fixed 0,97 0,88 1,08 0,62 861 1,36 0,87 2,11 0,18 799 0,78 0,64 0,96 0,02 799
Random 1,00 0,82 1,22 1,00 861 1,39 0,72 2,69 0,33 799 0,78 0,64 0,96 0,02 799
Risperidone De Deyn 1999 1,16 0,84 1,62 0,37 229
Herz unpublished 1,14 0,12 10,71 0,91 22 3,00 0,16 55,72 0,46 22
Schneider 2006 0,91 0,80 1,04 0,17 227 3,58 1,52 8,43 0,00 227 0,64 0,49 0,83 0,00 227
Brodaty 2003 0,82 0,59 1,14 0,23 337 1,60 0,85 3,02 0,15 337 0,49 0,28 0,86 0,01 337
Katz 1999 1,17 0,88 1,56 0,28 625 1,34 0,85 2,12 0,21 625 0,86 0,41 1,83 0,70 625
Mintzer 2006 1,01 0,74 1,38 0,94 473 1,05 0,62 1,79 0,84 473 0,89 0,44 1,77 0,73 473
RIS-BEL 14 2001 0,95 0,28 3,27 0,94 39 0,48 0,10 2,30 0,35 39
Deberdt 2005 2,72 0,82 9,05 0,10 290
Fixed 0,96 0,87 1,07 0,47 1952 1,50 1,13 1,98 0,00 1952 0,65 0,52 0,81 0,00 1723
Random 0,96 0,87 1,07 0,47 1952 1,61 1,09 2,37 0,02 1952 0,65 0,52 0,81 0,00 1723
Thioridazine Barnes 1982 0,86 0,36 2,02 0,72 34 2,00 0,42 9,50 0,38 34
Fixed 0,86 0,36 2,02 0,72 34 2,00 0,42 9,50 0,38 34
Random 0,86 0,36 2,02 0,72 34 2,00 0,42 9,50 0,38 34
Thiothixene Finkel 1995 0,14 0,01 2,56 0,19 32 0,33 0,01 7,62 0,49 32
Fixed 0,14 0,01 2,56 0,19 32 0,33 0,01 7,62 0,49 32
Random 0,14 0,01 2,56 0,19 32 0,33 0,01 7,62 0,49 32
Tiapride Allain 2000 0,63 0,30 1,32 0,22 205 0,84 0,27 2,67 0,77 205 0,13 0,02 0,99 0,05 205
Fixed 0,63 0,30 1,32 0,22 205 0,84 0,27 2,67 0,77 205 0,13 0,02 0,99 0,05 205
Random 0,63 0,30 1,32 0,22 205 0,84 0,27 2,67 0,77 205 0,13 0,02 0,99 0,05 205
global Drop-Outs Drop-Outs due to Inefficacy
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TOLERABILITY ANALYSIS 
The tests for heterogeneity indicated the fixed effects model to be appropriate for all 
pooled analyses of groups and single drugs with the exception of somnolence. The 
use of antipsychotics goes along with significantly higher rates of somnolence 
(RR = 2,7; p < 0,0001), death (RR = 1,6; p = 0,039), EPS (RR = 1,4; p = 0,006), and 
SAE (RR: 1.3; p=0.031). Agitation was lower when using antipsychotics (RR: 0,8; 
p = 0,012). For accidental injuries no difference was found between antipsychotics 
and placebo (RR = 0,97; p = 0,69) (see figure 5).  
There was no difference in tolerability profile between SGA and FGA. For the 
detailed analysis of FGA and SGA compared to placebo see table 3.  
Concerning single antipsychotic drugs the risk ratio for agitation was significant only 
for aripiprazole (RR = 0,57; p = 0,03). For haloperidol (RR: = 0,65; p = 0,18), and 
quetiapine (RR = 0,66; p = 0,49) the risk ratio was still moderate, yet not significant 
(no data for loxapine, thioridazine, thiothixene, perphenazine). Accidental injury (no 
data for loxapine, thioridazine, tiapride, thiothixene, pimozide, perphenazine), death 
(no data for loxapine, thioridazine, thiothixene, pimozide, perphenazine), and SAE 
(no data for loxapine, thioridazine, tiapride, thiothixene, pimozide, perphenazine) 
were not significantly different for any of the investigated single drugs. EPS was 
significantly worse for olanzapine (RR = 17,04; p = 0,006), haloperidol (RR = 2,02; 
p = 0,002), loxapine (RR = 2,75; p = 0,041), and risperidone (RR = 1,72; p = 0,002) 
(no data for thiothixene, pimozide, perphenazine).  
Concerning somnolence the random effects model had to be used (test for 
heterogeneity: Q value: 35,8; df(Q): 17,0; p = 0,005; I2: 52,5). Quetiapine (RR = 4,9; 
p < 0,0001), olanzapine (RR = 3,7; p < 0,0001) and risperidone (RR = 2,0; p = 0,000) 
induced significantly more somnolence than placebo. Data of FGA were only 
available for haloperidol (RR = 3,0; p = 0,07) and tiapride (RR = 1,01; p = 0,98) (no 
data for loxapine, thioridazine, thiothixene, pimozide, perphenazine). 
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FIGURE 5: POOLED ANALYSES OF TOLERABILITY CRITERIA AGITATION, ACCIDENTAL INJURY 
(AI), DEATH, EXTRAPYRAMIDAL SYMPTOMS (EPS), SERIOUS ADVERSE ADVENTS (SAE) AND 
SOMNOLENCE
 
Total: number of patients in analysis, FGA: First Generation Antipsychotic, SGA: Second Generation 
Antipsychotic 
Risk ratio and 95% CI
Risk Lower Upper 
ratio limit limit p-Value Total
Agitation All 0,773 0,632 0,945 0,012 3498
Agitation FGA 0,652 0,347 1,226 0,184 193
Agitation SGA 0,764 0,623 0,936 0,009 3496
AI All 0,973 0,853 1,112 0,691 3117
AI FGA 1,078 0,785 1,482 0,642 193
AI SGA 0,964 0,844 1,102 0,592 3115
Death All 1,564 1,024 2,390 0,039 4565
Death FGA 1,435 0,109 18,907 0,784 205
Death SGA 1,520 0,984 2,347 0,059 4359
EPS All 1,418 1,107 1,817 0,006 2506
EPS FGA 1,587 0,978 2,577 0,062 281
EPS SGA 1,363 1,021 1,818 0,036 2225
SAE All 1,254 1,020 1,541 0,031 3514
SAE FGA 1,316 0,651 2,663 0,444 193
SAE SGA 1,239 1,008 1,524 0,042 3512
Somnolence All 2,704 1,954 3,741 0,000 3883
Somnolence FGA 2,959 0,884 9,905 0,078 627
Somnolence SGA 2,870 2,080 3,960 0,000 3677
0,01 0,1 1 10 100
Favours Antipsychotic Favours Placebo
  
 
 
 
TABLE 4: OVERVIEW AND RESULTS OF CLINICAL TRIALS INCLUDED IN THE TOLERABILITY ANALYSES 
 Fixed = Fixed effects model, Random = Random Effects Model, RR = Risk ratio, Lower = Lower limit, Upper = Upper limit, Total = Total sample size 
Death SERIOUS ADVERSE EVENTS SOMNOLENCE AGITATION Accidental Injuries EPS
Antipsychotic Study name RR Lower Upper p-Value Total RR Lower Upper p-Value Total RR Lower Upper p-Value Total RR Lower Upper p-Value Total RR Lower Upper p-Value Total RR Lower Upper p-Value Total
Aripiprazole CN138005 2004 1,05 0,22 5,10 0,95 256 0,99 0,52 1,87 0,97 256
De Deyn 2005 2,89 0,12 70,08 0,51 208 1,71 0,79 3,69 0,17 208 1,20 0,33 4,35 0,78 208
Breder 2004 1,24 0,42 3,66 0,70 487 2,07 0,73 5,82 0,17 487 0,57 0,34 0,93 0,03 487 1,28 0,85 1,93 0,24 487 1,28 0,57 2,85 0,55 487
Fixed 1,25 0,53 2,97 0,61 951 1,23 0,76 2,02 0,40 464 2,07 0,73 5,82 0,17 487 0,57 0,34 0,93 0,03 487 1,28 0,85 1,93 0,24 487 1,25 0,63 2,48 0,52 695
Random 1,25 0,53 2,97 0,61 951 1,24 0,73 2,12 0,42 464 2,07 0,73 5,82 0,17 487 0,57 0,34 0,93 0,03 487 1,28 0,85 1,93 0,24 487 1,25 0,63 2,48 0,52 695
Haloperidol Tariot 2006 1,84 0,56 6,09 0,32 193 1,32 0,65 2,66 0,44 193 8,95 3,30 24,26 0,00 193 0,65 0,35 1,23 0,18 193 1,08 0,78 1,48 0,64 193
Allain 2000 2,04 0,19 22,14 0,56 204 1,15 0,46 2,86 0,77 204 1,93 1,17 3,18 0,01 204
De Deyn 1999 2,78 1,03 7,45 0,04 229
Petrie 1982 2,48 0,90 6,80 0,08 42
Fixed 1,88 0,65 5,48 0,25 397 1,32 0,65 2,66 0,44 193 2,88 1,65 5,02 0,00 626 0,65 0,35 1,23 0,18 193 1,08 0,78 1,48 0,64 193 2,02 1,29 3,17 0,00 246
Random 1,88 0,65 5,48 0,25 397 1,32 0,65 2,66 0,44 193 3,02 0,93 9,76 0,07 626 0,65 0,35 1,23 0,18 193 1,08 0,78 1,48 0,64 193 2,02 1,29 3,17 0,00 246
Loxapine Petrie 1982 2,32 0,83 6,50 0,11 41
Barnes 1982 9,90 0,59 166,78 0,11 36
Fixed 2,75 1,04 7,24 0,04 77
Random 2,75 1,04 7,24 0,04 77
Olanzapine Deberdt 2005 3,24 0,17 62,18 0,43 298 2,71 1,33 5,50 0,01 298 1,31 0,73 2,35 0,36 298 1,24 0,63 2,46 0,53 298
De Deyn 2004 1,86 0,43 8,03 0,41 649 4,34 1,06 17,81 0,04 649 0,55 0,26 1,18 0,13 649
Street 2000 3,30 0,19 58,61 0,42 206 3,84 0,95 15,60 0,06 206 4,53 1,48 13,91 0,01 206 1,33 0,47 3,74 0,59 206 1,26 0,71 2,23 0,42 206
Schneider 2006 0,47 0,05 4,48 0,51 242 1,05 0,55 1,99 0,89 242 4,87 2,18 10,86 0,00 242 0,71 0,30 1,70 0,44 242 1,15 0,64 2,07 0,64 242 17,04 2,25 128,95 0,01 242
F1D-MC-HGIC 2005 3,79 1,38 10,43 0,01 268 1,77 0,74 4,23 0,20 268
Fixed 1,60 0,56 4,58 0,38 1395 1,56 0,91 2,67 0,11 1097 3,69 2,39 5,70 0,00 1014 0,94 0,64 1,38 0,76 1395 1,28 0,93 1,77 0,13 1014 17,04 2,25 128,95 0,01 242
Random 1,60 0,56 4,58 0,38 1395 2,20 0,78 6,22 0,14 1097 3,69 2,39 5,70 0,00 1014 0,92 0,59 1,45 0,73 1395 1,28 0,93 1,77 0,13 1014 17,04 2,25 128,95 0,01 242
Quetiapine Schneider 2006 1,51 0,31 7,33 0,61 236 1,35 0,74 2,46 0,33 236 4,53 2,01 10,24 0,00 236 1,19 0,56 2,50 0,65 236 0,50 0,22 1,14 0,10 236 3,02 0,28 32,85 0,36 236
Ballard 2005 3,00 0,13 70,92 0,50 62
Zhong 2007 1,91 0,57 6,44 0,30 333 0,93 0,45 1,95 0,85 333 4,01 0,96 16,76 0,06 333 0,53 0,25 1,16 0,11 333
Tariot 2006 0,54 0,10 2,90 0,48 190 0,91 0,41 2,00 0,81 190 6,26 2,25 17,40 0,00 190 0,36 0,16 0,81 0,01 190 0,96 0,68 1,34 0,81 190
Fixed 1,38 0,62 3,10 0,43 821 1,09 0,73 1,63 0,66 759 4,93 2,75 8,82 0,00 759 0,69 0,40 1,19 0,18 426 0,87 0,64 1,19 0,39 426 0,63 0,30 1,32 0,22 569
Random 1,38 0,62 3,10 0,43 821 1,09 0,73 1,63 0,66 759 4,93 2,75 8,82 0,00 759 0,66 0,21 2,12 0,49 426 0,78 0,43 1,40 0,40 426 0,87 0,19 3,97 0,85 569
Risperidone Schneider 2006 0,56 0,06 5,27 0,61 227 0,79 0,38 1,67 0,54 227 3,10 1,29 7,47 0,01 227 0,60 0,22 1,60 0,30 227 0,80 0,39 1,61 0,52 227 16,71 2,18 128,22 0,01 227
Brodaty 2003 1,53 0,44 5,31 0,51 337 1,90 1,05 3,43 0,03 337 1,44 1,04 2,00 0,03 337 0,80 0,53 1,20 0,28 337 0,97 0,73 1,29 0,83 337 1,47 0,95 2,29 0,09 337
Katz 1999 1,76 0,69 4,53 0,24 625 1,16 0,74 1,83 0,52 625 2,33 1,34 4,07 0,00 625 0,68 0,39 1,20 0,18 625 0,83 0,65 1,05 0,12 625 1,88 1,04 3,39 0,04 625
Mintzer 2006 5,06 0,24 104,91 0,29 473 1,08 0,68 1,70 0,75 473 3,50 1,83 6,68 0,00 473 1,20 0,63 2,28 0,57 473 0,89 0,52 1,54 0,68 473
Deberdt 2005 2,22 1,08 4,57 0,03 290 1,11 0,61 2,02 0,74 290 0,77 0,36 1,63 0,49 290
De Deyn 1999 3,77 1,46 9,74 0,01 229
Fixed 1,60 0,80 3,20 0,19 1662 1,19 0,91 1,55 0,19 1662 2,03 1,61 2,54 0,00 2181 0,86 0,67 1,10 0,23 1952 0,87 0,74 1,03 0,11 1952 1,72 1,21 2,44 0,00 1189
Random 1,60 0,80 3,20 0,19 1662 1,19 0,88 1,61 0,25 1662 2,35 1,64 3,35 0,00 2181 0,86 0,67 1,10 0,23 1952 0,87 0,74 1,03 0,11 1952 2,07 1,03 4,19 0,04 1189
Thioridazine Barnes 1982 7,00 0,39 125,99 0,19 34
7,00 0,39 125,99 0,19 34
7,00 0,39 125,99 0,19 34
Tiapride Allain 2000 1,01 0,06 15,93 0,99 205 1,01 0,39 2,59 0,98 205 0,90 0,49 1,66 0,73 205
Fixed 1,01 0,06 15,93 0,99 205 1,01 0,39 2,59 0,98 205 0,90 0,49 1,66 0,73 205
Random 1,01 0,06 15,93 0,99 205 1,01 0,39 2,59 0,98 205 0,90 0,49 1,66 0,73 205
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Data on akathisia were rare. Dichotomous data were only provided by six studies 
[23, 24, 33, 42, 48, 49] and continuous data via Barnes Global Scale only by two [31, 
36]. There were no data for FGA. For the occurrence of akathisia measured as event, 
there is no significant difference found between SGA and Placebo (see figure 6). The 
analysis of Barnes Global Scale shows a tendency for SGA to be superior compared 
to placebo, but with no significance (see figure 7). The risperidone treatment arm 
from the trial by Herz goes along with an advantage for the antipsychotic 
(Hedges’s g = -1,128; CI: -2,040 – -0,217; p = 0,015). 
For the analysis of dyskinesia data was only provided for SGA. Four trials were 
included in the analysis of dichotomous data on dyskinesia [24, 32, 33, 49] and five in 
the analysis of continuous data using the Abnormal Involuntary Movement Scale 
(AIMS) [31, 39, 44, 46, 48]. For both analyses no significant results were found 
between antipsychotics and placebo (see figure 8 and 9).  
For the analysis of the occurrence of parkinsonism seven studies provided 
dichotomous data [23, 24, 32, 33, 42, 48, 49] and eight continuous data (Simpson-
Angus Scale, SAS) [21, 31, 36, 37, 39, 44, 46, 48]. Pooled results from dichotomous 
and continuous data revealed a higher occurrence of parkinsonism or parkinsonoid in 
the antipsychotic group (see figure 10 and 11). In the dichotomous data set the 
random effects model has to be chosen which was of borderline significance only 
(RR = 1,679; p = 0,053).  
Within the single drug analysis significant effects were only found for haloperidol and 
risperidone. For risperidone this effect was confirmed in the dichotomous data set 
only (RR = 1,754; p = 0,014; fixed model to be applied). In the continuous data set 
the random effects model had to be chosen, which was not significant. 
 
Results 
 
23 
 
FIGURE 6: AKATHISIA ANALYSIS
 
 
 
FIGURE 7: BARNES GLOBAL AKATHISIA SCALE
  
Study nameAntipsychotic Statistics for each study Risk ratio and 95% CI
Risk Lower Upper 
ratio limit limit p-Value
Deberdt 2005Olanzapine 0,922 0,236 3,606 0,907
F1D-MC-HGAO 2005 1,377 0,450 4,216 0,576
Street 2000 0,591 0,154 2,274 0,444
Schneider 2006 4,248 0,175 103,212 0,374
F1D-MC-HGIC 2005 0,169 0,007 4,119 0,276
0,948 0,474 1,896 0,881
0,948 0,474 1,896 0,881
Schneider 2006Quetiapine 4,516 0,186 109,690 0,354
1,203 0,128 11,290 0,871
1,209 0,094 15,540 0,884
Deberdt 2005Risperidone 0,799 0,195 3,274 0,756
0,799 0,195 3,274 0,756
0,799 0,195 3,274 0,756
Overall 0,935 0,514 1,703 0,827
0,932 0,509 1,705 0,818
0,01 0,1 1 10 100
Favours Antipsychotic Favours Placebo
Olanzapine pooled Fixed Effects Model
Olanzapine pooled Random Effects Model
Quetiapine pooled Fixed Effects Model
Quetiapine pooled Fixed Effects Model
Risperidone pooled Fixed Effects Model
Risperidone pooled Random Effects Model
All  pooled Fixed Effects Model
All  pooled Random Effects Model
Paleacu 2007 0,333 0,014 7,724 0,493
StudyAntipsychotic Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
De Deyn 2005Aripiprazole -0,103 -0,379 0,173 0,464
Herz unpublishedOlanzapine -0,320 -1,435 0,795 0,574
Herz unpublishedRisperidone -1,128 -2,040 -0,217 0,015
All pooled Fixed Effects Model Overall -0,196 -0,453 0,061 0,135
All pooled Random Effects Model -0,196 -0,453 0,061 0,135
-1,00 -0,50 0,00 0,50 1,00
Favours Antipsychotic Favours Placebo
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FIGURE 8: DYSKINESIA ANALYSIS
 
FIGURE 9: ABNORMAL INVOLUNTARY MOVEMENT SCALE (AIMS)
 
Study nameAntipsychotic Statistics for each study Risk ratio and 95% CI
Risk Lower Upper 
ratio limit limit p-Value
Deberdt 2005Olanzapine 0,922 0,285 2,984 0,892
De Deyn 2004 0,347 0,112 1,077 0,067
Schneider 2006 1,420 0,090 22,435 0,803
F1D-MC-HGIC 2005 3,559 0,186 68,157 0,399
0,673 0,316 1,433 0,304
0,679 0,313 1,477 0,329
Schneider 2006Quetiapine 3,021 0,278 32,850 0,364
3,021 0,278 32,850 0,364
3,021 0,278 32,850 0,364
Deberdt 2005Risperidone 0,839 0,252 2,797 0,775
Schneider 2006 3,341 0,308 36,295 0,322
1,111 0,379 3,253 0,848
1,123 0,372 3,388 0,837
Overall 0,864 0,475 1,572 0,632
0,876 0,474 1,618 0,672
0,01 0,1 1 10 100
Favours Antipsychotic Favours Placebo
Quetiapine pooled Fixed Effects Model
Quetiapine pooled Random Effects Model
Risperidone pooled Fixed Effects Model
Risperidone pooled Random Effects Model
Olanzapine pooled Fixed Effects Model
Olanzapine pooled Random Effects Model
All  pooled Fixed Effects Model
All  pooled Random Effects Model
StudyAntipsychotic Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
De Deyn 2005Aripiprazole -0,071 -0,348 0,207 0,618
Aripiprazole pooled Fixed Effects Model -0,071 -0,348 0,207 0,618
Aripiprazole pooled Random Effects Model -0,071 -0,348 0,207 0,618
Tariot 2006Haloperidol 0,249 -0,043 0,542 0,095
Haloperidol pooled Fixed Effects Model 0,249 -0,043 0,542 0,095
Haloperidol pooled Random Effects Model 0,249 -0,043 0,542 0,095
Paleacu 2007Quetiapine 0,349 -0,278 0,977 0,275
Tariot 2006 0,051 -0,241 0,344 0,730
Zhong 2007 0,043 -0,197 0,283 0,725
Quetiapine pooled Fixed Effects Model 0,071 -0,107 0,248 0,435
Quetiapine pooled Random Effects Model 0,071 -0,107 0,248 0,435
Mintzer 2006Risperidone 0,000 -0,180 0,180 1,000
Risperidone pooled Fixed Effects Model 0,000 -0,180 0,180 1,000
Risperidone pooled Random Effects Model 0,000 -0,180 0,180 1,000
All  pooled Fixed Effects ModelOverall 0,049 -0,059 0,156 0,374
All  pooled Random Effects Model 0,049 -0,059 0,156 0,374
-1,00 -0,50 0,00 0,50 1,00
Favours Antipsychotic Favours Placebo
Test for heterogeneity:
Aripiprazole: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 % Haloperidol: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 % 
Quetiapine: Chi2=0,83, df=2,00, (p=0,66), I2=0,00 % Risperidone: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 %
Olanzapine: Chi2=8,40, df=6,00, (p=0,21), I2=28,58 % Overall: Chi2=3,68, df=5,00, (p=0,60), I2=0,00 %
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FIGURE 10: PARKINSONISM ANALYSIS
 
FIGURE 11: SIMPSON-ANGUS SCALE (SAS)
 
Study nameAntipsychotic Statistics for each study Risk ratio and 95% CI
Risk Lower Upper 
ratio limit limit p-Value
Deberdt 2005Olanzapine 1,075 0,655 1,764 0,774
F1D-MC-HGAO 2005 2,294 0,608 8,662 0,220
De Deyn 2004 0,532 0,290 0,973 0,040
Street 2000 0,739 0,243 2,249 0,594
Schneider 2006 7,100 1,590 31,708 0,010
F1D-MC-HGIC 2005 2,384 1,098 5,175 0,028
1,114 0,816 1,521 0,497
1,371 0,722 2,604 0,335
Schneider 2006Quetiapine 3,777 0,748 19,064 0,108
Paleacu 2007 1,000 0,067 14,904 1,000
2,658 0,663 10,659 0,168
2,658 0,663 10,659 0,168
Deberdt 2005Risperidone 1,572 0,985 2,508 0,058
Schneider 2006 5,847 1,243 27,502 0,025
1,754 1,122 2,743 0,014
2,443 0,724 8,240 0,150
Overall 1,323 1,029 1,701 0,029
1,679 0,993 2,838 0,053
0,01 0,1 1 10 100
Favours Antipsychotic Favours Placebo
Quetiapine pooled Fixed Effects Model
Quetiapine pooled Random Effects Model
Risperidone pooled Fixed Effects Model
Risperidone pooled Random Effects Model
All  pooled Fixed Effects Model
All  pooled Random Effects Model
Olanzapine pooled Fixed Effects Model
Olanzapine pooled Random Effects Model
Test for heterogeneity:
Olanzapine: Chi2=17,02, df=5,00, (p=0,005), I2=70,62 % Quetiapine: Chi2=0,68, df=1,00, (p=0,41), I2=0,00 %
Risperidone : Chi2=2,53, df=1,00, (p=0,11), I2=60,54 % Overall: Chi2=23,90 df=9,00, (p=0,005), I2=62,35 %
StudyAntipsychotic Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
De Deyn 2005Aripiprazole 0,228 -0,051 0,507 0,109
0,228 -0,051 0,507 0,109
0,228 -0,051 0,507 0,109
Tariot 2006Haloperidol 0,625 0,307 0,944 0,000
0,625 0,307 0,944 0,000
0,625 0,307 0,944 0,000
Herz unpublishedOlanzapine -0,154 -1,263 0,956 0,786
-0,154 -1,263 0,956 0,786
-0,154 -1,263 0,956 0,786
Zhong 2007Quetiapine -0,182 -0,422 0,058 0,138
Tariot 2006 0,000 -0,313 0,313 1,000
Paleacu 2007 0,410 -0,220 1,039 0,202
-0,071 -0,253 0,112 0,448
-0,032 -0,288 0,224 0,807
Herz unpublishedRisperidone 0,000 -0,845 0,845 1,000
Katz 1999 0,222 0,042 0,402 0,016
RIS-BEL 14 2001 -0,647 -1,286 -0,008 0,047
Mintzer 2006 0,404 0,222 0,586 0,000
0,269 0,145 0,393 0,000
0,139 -0,164 0,443 0,367
Overall 0,205 0,113 0,297 0,000
0,201 0,059 0,343 0,005
-1,00 -0,50 0,00 0,50 1,00
Favours Antipsychotic Favours Placebo
Risperidone pooled Fixed Effects Model
Risperidone pooled Random Effects Model
Quetiapine pooled Fixed Effects Model
Quetiapine pooled Random Effects Model
Olanzapine pooled Fixed Effects Model
Olanzapine pooled Random Effects Model
All pooled Fixed Effects Model
All pooled Random Effects Model
Haloperidol pooled Fixed Effects Model
Haloperidol pooled Random Effects Model
Aripirazole pooled Fixed Effects Model
Aripirazole pooled Random Effects Model
Test for heterogeneity:
Aripiprazole: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 % Haloperidol: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 % 
Olanzapine: Chi2=0,00, df=0,00, (p=1,00), I2=0,00 % Quetiapine: Chi2=3,26, df=2,00, (p=0,20), I2=38,62 %
Risperidone : Chi2=10,65, df=3,00, (p=0,01), I2=71,82 % Overall: Chi2=30,83, df=9,00, (p=0,00), I2=70,81 %
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COGNITION ANALYSIS 
The pooled analyses of all antipsychotics compared to placebo revealed a trend 
towards a deterioration in cognitive functioning, however, with very small effect size 
(Hedge’s g random effects model: -0,06; p = 0,30, fixed effects model: -0,10; 
p = 0,04). The random effects model had to be chosen due to heterogeneity of 
variance (Q value: 20,4; df(Q): 12,0; p = 0,06; I2: 41,2). 
For the SGA the respective data could be taken from figure 12. The results are quite 
alike. Even if choosing the fixed effects model, a Hedges’s g of 0,1 is minimal. The 
mean difference in MMSE score between SGA and placebo would only be 0,3 points 
(calculated as a weighted difference in means using Comprehensive Meta-analysis 
version two [20]). The results of the sensitivity analysis were similar. The funnel plot 
did not suggest a publication bias. 
Both trials with aripiprazole showed a worsening with the antipsychotic, being 
significant in one trial [31], and not significant in the other [22]. The pooled analysis is 
only significant for the fixed effects model (p = 0,012), but not for the random effects 
model (p = 0,229). Three studies on olanzapine reported no or minimal differences 
between placebo [23, 42, 43]. A fourth study, that included patients with a particularly 
high MMSE Score of 21,5 points found a significant deterioration with olanzapine as 
compared to placebo [24]. The pooled analysis did not reveal significant results, 
neither in the fixed effects model (p = 0,540), nor in the random effects model (p = 
0.995). The three studies with quetiapine consistently showed no difference 
compared to placebo [43, 44, 46]. Results of the fixed and random effects models are 
identical (p = 0,529). The two studies with risperidone exhibited no difference as 
compared to placebo [21, 43]. The pooled analysis results for risperidone are 
identical in the fixed and random effects models (p = 0,790). For haloperidol we 
found one short-term trial with no differences to placebo (Hedges’s g = -0,037; 95% 
CI: -0,373 – 0,300; p = 0,831) [44]. For one long-term trial the results were very much 
the same (Hedges’s g = -0,107; 95% CI: -0,571 – 0,357; p = 0,651) [45]. The pooled 
results for haloperidol are identical for the fixed and the random effects model 
(Hedges’s g = -0,061; 95% CI: -0,333 – 0,211; p = 0,661). 
Results 
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 Figure 12: Changes in the Mini Mental State Exam during treatment with 
antipsychotics. Pooled analysis of second generation antipsychotics compared to 
placebo
 
  
Study Antipsychotic Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
CN138005 2004Aripiprazole -0,049 -0,326 0,229 0,730
De Deyn 2005 -0,498 -0,794 -0,202 0,001
-0,259 -0,461 -0,057 0,012
-0,270 -0,710 0,170 0,229
F1D-MC-HGAO 2005Olanzapine 0,074 -0,211 0,359 0,612
Street 2000 0,225 -0,114 0,564 0,194
F1D-MC-HGIC 2005 -0,411 -0,675 -0,148 0,002
Sultzer 2008 0,186 -0,233 0,605 0,384
-0,049 -0,205 0,107 0,540
0,001 -0,315 0,317 0,995
Tariot 2006Quetiapine -0,179 -0,508 0,150 0,287
Sultzer 2008 -0,031 -0,480 0,418 0,892
Zhong 2007 0,000 -0,240 0,240 1,000
-0,057 -0,235 0,121 0,529
-0,057 -0,235 0,121 0,529
Sultzer 2008Risperidone -0,034 -0,475 0,407 0,880
RIS-BEL 14 2001 -0,089 -0,766 0,589 0,798
-0,050 -0,420 0,319 0,790
-0,050 -0,420 0,319 0,790
Overall -0,101 -0,198 -0,003 0,044
-0,066 -0,202 0,070 0,343
-1,00 -0,50 0,00 0,50 1,00
Worse with Antipsychotic Worse with Placebo
Aripirazole pooled Fixed Effects Model
Aripirazole pooled Random Effects Model
Olanzapine pooled Fixed Effects Model
Olanzapine pooled Random Effects Model
Quetiapine pooled Fixed Effects Model
Quetiapine pooled Random Effects Model
Risperidone pooled Fixed Effects Model
Risperidone pooled Random Effects Model
All pooled Fixed Effects Model
All pooled Random Effects Model
Test for heterogeneity:
Aripiprazole: Chi2=4.71, df=1.00, (p=0.03), I2=78.77 % Olanzapine: Chi2=11.70, df=3.00, (p=0.01), I2=74.35 % 
Quetiapine: Chi2=0.76, df=2.00, (p=0.69), I2=0.00 % Risperidone: Chi2=0.02, df=1.00, (p=0.89), I2=0.00 %
Overall: Chi2=20.26, df=10,00, (p=0.03), I2=50.56 %
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DISCUSSION 
DEMENTIA, BPSD AND ITS TREATMENTS 
The word “Dementia” is derived from the Latin “de” (out of) and “mens” (mind) and 
means “out of one’s mind”. In the early 19th century the French Psychiatrist Jean 
Etienne Dominique Esquirol gave a short but accurate definition of dementia as “a 
cerebral affection … characterized by a weakening of the sensibility, understanding, 
and will” [50]. It is remarkable that Esquirol not only focuses on cognitive impairment, 
but also on other manifestations, such as apathy, deterioration in social behaviour, 
occasional aggressiveness, delusional ideas and hallucinations [51]. His definition 
does not deviate a great deal from the ones more than 150 years later. The British 
dementia guideline defines dementia “as a clinical syndrome … characterized by 
global cognitive impairment, which represents a decline from previous level of 
functioning, and is associated with impairment in functional abilities and, in many 
cases, behavioural and psychiatric disturbances” [52].  
Several of these formal definitions exist, such as the mentionable International 
Classification of Diseases (ICD) 10: “a syndrome due to disease of the brain, usually 
of a chronic or progressive nature, in which there is disturbance of multiple higher 
cortical functions, including memory, thinking, orientation, comprehension, 
calculation, learning capability, language, and judgment. Consciousness is not 
impaired. Impairments of cognitive function are commonly accompanied, occasionally 
preceded, by deterioration in emotional control, social behaviour, or motivation. The 
syndrome occurs in Alzheimer’s disease, in cerebrovascular disease, and in other 
conditions primarily or secondarily affecting the brain” [53]. 
Dementia is a very heterogeneous disease. Multiple diagnostic entities exist, of which 
Alzheimer’s disease (AD) is the most common. Other frequently occurring dementias 
are Vascular Dementia (e.g. multi-infarct dementia, Binswanger’s dementia), Lewy 
Body Dementia (e.g. Parkinson’s disease, diffuse Lewy Body Dementia, and Lewy 
Body variant of AD) and other forms (e.g. Frontotemporal Lobar Degeneration, 
Creutzfeld-Jacob Disease, Corticobasale Degeneration, potentially reversible 
dementias).  
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Each dementia has its own clinical correlate, its own aetiology and pathogenesis, 
which is multifactorial. In AD the following hypothesis are discussed and intensively 
investigated [54-61]: 
• cholinergic dysfunction 
• beta-amyloid toxicity 
• tau-hyperphosphorilation 
• oxidative damage 
• mitochondrial dysfunction 
• synaptic dysfunction 
• inflammation reactions through glia, cytotoxic activation 
• deranged glucose metabolism 
• deranged lipid metabolism 
• proteomic dysfunction 
• calcium dysregulation 
• polysaccharide deposits 
An overview of these pathogenic interactions gives Figure 13. One key finding is that 
many degenerative processes are mediated through inflammation. Inflammation may 
accelerate and therefore constitute the degradation of Amyloid Precursor Protein to 
Aβ and may induce many other neuropathological alterations of AD. 
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FIGURE 13: PATHOGENESIS OF ALZHEIMER’S DISEASE ACCORDING TO [60] 
 
APP: Amyloid Precursor Protein, Aβ: beta-amyloid  
 
TREATMENT OPTIONS 
The three main symptoms of AD are cognitive impairment, non-cognitive impairments 
- also known as behavioural and psychological symptoms of dementia (BPSD) - and 
impairment of daily living activities. Cognitive decline was the primary target in 
investigating drugs for dementia. BPSD and impairment of daily living activities have 
long been neglected in research.  
There are different therapeutic approaches targeting each main symptom. 
Pharmacological treatment approaches only exist for two hypotheses of the complex 
pathogenesis of AD and primarily target cognitive decline: cholinergic dysfunction 
and cytotoxicity. 
 
GENERAL TREATMENT RECOMMENDATIONS 
Acetylcholine Esterase Inhibitors (AChEI), such as donepezil, rivastigmine and 
galantamine inhibit the acetylcholine esterase in the synaptic gap, resulting in higher 
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acetylcholine levels. Higher levels of acetylcholine should improve cognitive 
functioning. In clinical trials they have shown to modulate the course of AD in the 
sense that cognitive decline has been delayed for about one year [62]. Galantamine 
additionally modifies psychotic symptoms [63, 64]. AChEI are approved for early and 
middle-stage dementia. Common side effects are gastrointestinal symptoms such as 
nausea, vomiting or diarrhoea and symptoms of the central nervous system like 
dizziness, confusion, insomnia or fatigue.    
Memantine is an NMDA receptor modulator. It lowers the synaptic concentration of 
glutamate in neurons. Chronically elevated synaptic glutamate levels, as in AD, 
reduce neuronal functioning and lead to neuronal death. Furthermore, memantine 
lowers the tau-hyperphosphorilation. Memantine is approved for late stage dementia 
only. Common side effects are dizziness, agitation, fatigue and nausea. The Institute 
for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im 
Gesundheitswesen, IQWIG) evaluated the effect of memantine on cognition in AD 
patients and certified its benefits [65]. There are indicators of a beneficial influence of 
memantine in AD with regard to daily living activities [65]. 
 
GUIDELINES FOR ANTI-DEMENTIVE DRUGS  
According to the German S3 Guideline “Dementias” [66] and the dementia guideline 
of the European Federation of Neurological Societies (EFNS) [67] 
acetylcholinesterase inhibitors (AChEIs)  are recommended for mild to moderate 
Alzheimer  and mixed dementia. Memantine is recommended for moderate to severe 
Alzheimer and mixed dementia.   
The treatment of vascular dementia with AChEIs or memantine lacks substantiation 
and is thus not approved by the S3 Guideline. The EFNS guideline regards donepezil 
as a treatment option. 
Pharmacologic treatment of mild to moderate Parkinson disease dementia and Lewy 
Body dementia with rivastigmine is effective and therefore recommended by the S3 
guideline. The EFNS guideline uses the terms “can be considered” in relation to 
AChEIs.  
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NON-PHARMACOLOGICAL INTERVENTIONS 
Apart from pharmacologic treatment approaches there are psychosocial 
interventions. Examples of psychosocial interventions are cognitive training, 
occupational therapy or physical activity. Studies in this field often have small 
numbers of participants, very heterogeneous outcomes and methodological deficits 
[66].  
Cognitive training can be sub-divided into compensatory and restorative strategies 
and reminiscence therapy. “Compensatory strategies aim to teach new ways of 
performing cognitive tasks by ‘working around’ cognitive deficits” and “restorative 
strategies attempt to improve functioning in specific domains with the ultimate goal of 
returning functioning in those domains to premorbid levels” [68]. A Cochrane Review 
could find neither benefits nor harm through cognitive training [69], whereas a meta-
analysis by Sitzer et al. found benefits for cognitive training [68]. The effect sizes for 
restorative strategies were higher than for compensatory strategies (0.54 vs. 0.36). 
The analysis of the IQWiG concludes some benefit with cognitive training [70].  
Reminiscence therapy deals with the individual history of a patient. A Cochrane 
review found significant positive results for cognition and mood of the patient and 
significant less strain for the caregiver [71]. 
Occupational therapy is an intervention that targets the maintenance of daily living 
activities and an improvement in the quality of living in individual everyday life. Only 
few studies exist with small numbers of participants and heterogeneous endpoints. A 
report by the German Institute for Medical Documentation and Information 
(Deutsches Institut für Medizinische Dokumentation und Information, DIMDI) 
analysed different nursing concepts and could not find evidence for occupational 
therapy and others (e.g. validation, relaxation, sensory stimulation) on the basis of 
current study results [72]. 
Physical activity is a supportive intervention with the aim to slow down cognitive 
decline. Yet there is not enough evidence for clear recommendations, as a Cochrane 
review suggests [73]. 
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TREATMENT OF BPSD 
Antipsychotics are commonly used to treat BPSD. They reduce thinking and 
perception disorders, anxiety, tension and agitation. But they do not influence 
consciousness and intellectual abilities in patients with psychotic disorders. 
Antipsychotics can be classified to their chemical structure (e.g. butyrophenones), 
antipsychotic potency or how they act. Antipsychotics with a high potency usually 
have in low or medium dosages an antipsychotic effect without sedating the patient. 
Low potency antipsychotics have primarily sedating properties in low to medium 
dosages with only minor antipsychotic properties.  
All antipsychotics act as an antagonist on dopamin-2 (D2) receptors. The 
antipsychotic properties correlate positively with the affinity towards the D2 receptors. 
The second generation antipsychotics predominantly have an antagonistic effect on 
serotonine-2 (5HT-2) receptors as well. Atypical antipsychotics have replaced 
conventional ones in many fields due to their different side-effect profile. They are 
called atypical, because they cause a typical side-effect, extrapyramidal symptoms 
(EPS) to a lower extent.  
Antipsychotics are originally used for the treatment of schizophrenia, but also for 
psychotic depression and mania. Schizophrenia is definitely the most important 
indication for the use of antipsychotics. Antipsychotic therapy is recommended to be 
implemented upon the first manifestations of acute symptoms of schizophrenia [74]. 
Antipsychotics are also approved for relapse prevention of schizophrenia and mania. 
Antipsychotic agents have potential side effects like vegetative disorders such as a 
decrease in blood pressure, orthostatic hypotension, changes in the 
electrocardiogram (especially QT prolongation), sweating, dry mouth, constipation, 
impotence, ejaculation disorders and anorgasmia [75]. Further they can cause weight 
gain and a metabolic syndrome, as well as EPS such as parkinsonism, akathisia, 
somnolence, dyskinesia and agitation. For patients with Parkinson dementia or Lewy 
body dementia first, and many second, generation antipsychotics are 
contraindicated, because they worsen the symptoms of Parkinson disease and cause 
attacks of somnolence. Antipsychotics that can be considered for these disorders are 
clozapine and, although less-well substantiated, quetiapine. 
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GUIDELINES FOR TREATMENT OF BPSD 
BPSD can be treated with psychosocial intervention or psychotropics. The German 
S3 guideline recommends the analysis of psychosocial findings prior to 
administration of psychotropics such as antipsychotics, benzodiazepines, anti-
depressants or anti-epileptics. Should the psychosocial intervention fail, be 
insufficient or not available, then this is an indication for a pharmacological 
intervention [66]. Behavioural and psychological symptoms of dementia are clusters 
of various symptoms. For each symptom cluster the German S3 guideline gives 
specific therapeutic suggestions. The cluster “affective disorders” includes 
depression and anxiety. Antidepressants, with the exception of tricyclic 
antidepressants, are recommended for depression. For anxiety there is no evidence-
based pharmacologic treatment. Another cluster is “hyperactivity”, including agitation 
and aggressive behaviour. Haloperidol is not recommended for agitation, possibly for 
aggressiveness. Risperidone is effective in agitation and aggressive behaviour, as is 
aripiprazole. Olanzapine is not approved. Apart from antipsychotics, anticonvulsive 
drugs such as carbamazepine are recommended. There is weak evidence in favour 
of the antidepressant citalopram. However, implementation in the case of agitation 
might be justified. For the cluster “psychotic symptoms” the S3 guideline only 
suggests the SGAs risperidone and aripiprazole.   
In summary, the S3 guideline only recommends the two SGAs risperidone and 
aripiprazole. In the case of olanzapine the data are too heterogeneous and its 
secondary anticholinergic action is unfavourable. 
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CRITICAL REVIEW ON THE ROLE OF ANTIPSYCHOTICS IN THE TREATMENT OF 
BPSD 
In 2005 and 2006 the Food and Drug Administration (FDA) published some “dear 
doctor” letters, respectively black-box warnings, in which they “determined that the 
treatment of behavioural disorders in elderly patients with dementia with atypical 
(second generation) antipsychotic medications is associated with increased mortality” 
[9] based on a meta-analysis by Schneider [76]. Additionally, “Cerebrovascular 
adverse events (e.g., stroke, transient ischemic attack), including fatalities, were 
reported in patients (mean age 85 years; range 73-97) in trials with risperidone in 
elderly patients with dementia-related psychosis. In placebo-controlled trials, there 
was a significantly higher incidence of cerebrovascular adverse events in patients 
treated with risperidone compared to patients treated with a placebo. RISPERDAL® 
is not approved for the treatment of patients with dementia-related psychosis” [77]. It 
is unclear to which study the FDA refers in the full prescribing information, but a 
meta-analytical summery revealed an significant increased risk for CVAE under 
risperidone treatment compared to placebo (OR: 3,43; CI: 1,60 – 7,32; p = 0,001) [6]. 
In Germany risperidone is approved for the treatment (up to six weeks) of persistent 
aggression in patients with mild to moderate Alzheimer’s dementia in the following 
cases: no response to non-pharmalogical interventions and a risk of endangerment 
to self and others [78]. 
Herrmann asked in 2005 “Do atypical antipsychotics cause stroke?” and answered 
his question as followed: “Results … suggested higher rates of CVAEs in drug 
treated subjects” [79]. Further research confirmed these findings: Kleijer et al. 
delivered a more sophisticated illustration: they found in a case control study that 
current and recent exposure to antipsychotics were associated with an increased risk 
of CVAE compared with non-users (OR: 1,7; CI: 1,4 – 2,2). The OR is elevated for a 
history of use for less than one week (OR: 9,9; CI: 5,7 – 17,2). The risk decreases 
with time and is comparable to non-users after 3 months of use (OR: 1,0;                
CI: 0,7 – 1,3). Cumulative exposure was not associated with an increase in risk. They 
conclude that the risk of CVAE in elderly and demented patients associated with 
antipsychotics is elevated especially during the first weeks of treatment. This risk 
decreases over time and is back at base level after 3 months of treatment; thus 
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chronic use is not associated with CVAE [80]. A review analyzing clinical trials and 
observational studies by Sacchetti and co-workers presents similar data [81]. All 
these results correspond, as the studies included in the meta-analysis by Schneider 
and colleagues, which grounded the FDA warnings, mostly have a maximal duration 
of 3 months [76].  
The rate of death seems to be elevated under antipsychotic treatment. Schneider 
calculated in a meta-analysis an Odds Ratio (OR) for SGA alone of 1.54 (CI: 1,06 – 
2,23; p = 0,02), which reflects an occurrence of 3,5% for SGA, respectively 2,3% for 
placebo [76]. Liperoti and colleagues performed a retrospective cohort study, in 
which they found that the rate of death for users of FGA (hazard ratio [HR]: 1,26; 
95% CI: 1,13 – 1,42) was higher than in SGA-users [82]. A two year prospective 
study in nursing homes and hospitals established that neither the use of atypical 
antipsychotics nor the use of typical ones increased mortality or hospital admissions 
[83]. As results from different type of studies are heterogeneous, there is a need to 
orientate on the highest level of evidence, which is provided by double blind 
randomised trials, and, of course, meta-analysis. Thus, in view of the various and 
frequent side-effects, respectively adverse events, treatment of BPSD with 
antipsychotics, as a mainstay of pharmacological therapy, had to be re-evaluated. 
Bullock, for example, suggested that “international guidelines are now required that 
direct prescribers in the appropriate use of alternative therapies for BPSD. AChEIs, 
particularly rivastigmine, can delay the onset and reduce the severity of 
neuropsychiatric symptoms in dementia, and decrease the requirement for 
antipsychotic and other psychotropic medications” [8]. 
In their work Jeste and colleagues mention, that “because of the recent black-box 
warnings about strokes and mortality with atypical antipsychotics …, some clinicians 
have begun to switch to the older typical antipsychotic agents” [84]. However, this is 
actually regarded critically by Hermann and Lanctot. Their “review suggests that 
there is no rationale to revert to the use of typical antipsychotics for BPSD given that 
their use is clearly associated with increased EPS, probably similar rates of 
cerebrovascular adverse events and mortality, and worsened cognition” [10]. Many 
experts still see the need for antipsychotics even though with a more stringent 
indication, e.g. “when severe and distressing symptoms are occurring...and when the 
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affected individual or others are at risk” [85]. Meeks and Jeste give the advice that 
“when treatment becomes necessary, atypical antipsychotics are one of several off-
label treatment options but, if chosen, should be used judiciously in the context of 
shared-decision making, close monitoring, and minimization of dose/treatment 
duration” [86]. 
In conclusion: BPSD needs to be treated and effective treatment options are rare. 
Therefore, clinicians cannot abandon antipsychotics. Their application is off-label and 
their use should be minimized: Only as much as necessary and only as long as 
needed.  
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AIMS, HYPOTHESIS AND METHODS  
The question we asked was: Are first generation antipsychotics superior to second 
generation ones, or vice versa? The appropriate way of answering this question is by 
setting up a study, or, if enough studies exist, by performing a meta-analysis. 
Systematic reviews and meta-analysis are considered important instruments in the 
evaluation of medical treatments and are rated in guidelines with the highest grade of 
evidence.  
Approximately two to three million articles are published in about 10,000 medical 
journals every year [87]. A general practitioner, wishing to keep up to date with the 
developments in this field, would have to read 19 articles per day [88]. There are at 
least 150 randomised controlled trials for the treatment of schizophrenia, comparing 
SGAs and FGAs. As it is so extremely difficult to maintain an overview over this 
incredible flood of studies, meta-analysis has developed into an essential tool for 
researchers and clinicians [89].  
What other options do clinicians and researchers have? They could view individual 
studies and base their treatment decision on these results. It is however unclear 
which of the 150 schizophrenia trials comparing atypical and conventionals to select. 
The random choice of any of the 150 studies could lead to a biased treatment 
decision. In consequence, the patient might not receive the optimal therapy. In such 
cases, the methodology of choice is a meta-analysis as it includes an extensive 
search for papers in several databases and hand search of journals. Only studies 
fulfilling a certain pre-defined standard will be included in the analysis. Furthermore, 
publication biases can be detected. Studies with negative results are less likely to be 
published. This publication bias can be detected with a funnel plot [19].  
The non-observance of possible important differences across studies is the most 
popular criticism of meta-analysis. This is also known as the problem of comparing 
apples and oranges. Gene Glass, one of the pioneers of this method, said that this is 
alright as long as you want to give a statement about fruit [90]. Of course, studies 
included in meta-analysis do differ and the question of inclusion is always an 
individual one. But it should be not forgotten, that meta-analyses always address 
broader questions than individual studies [91]. Another point of criticism is that meta-
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analysis is so complicated, that mistakes are inevitable and reviewers are unable to 
detect all of these, as verbalized by John C. Bailar [92]. Many meta-analyses do 
indeed contain mistakes. But these are more a problem of the persons performing a 
meta-analysis than a problem of the method itself. Other studies contain mistakes 
and errors as well. Bailar “still prefer(s) conventional narrative reviews of the 
literature, a type of summary familiar to readers of the countless review articles on 
important medical issues” [92]. A conventional or narrative review is subject to the 
same biases as a systematic review and meta-analysis. A systematic review will 
assess the results of an extensive search according to several quality standards. In a 
narrative review with no systematic approach, study selection might be arbitrary. In 
meta-analysis the focus is on the effect size, in narrative reviews on the p-value. 
Even small effect sizes can be significant, but have no clinical relevance. On the 
other hand, a large effect size is not significant because it is underpowered. 
Furthermore, a narrative review will not be able to assess the pattern of dispersion 
and the relationship to other variables, whereas meta-analysis provides tools to do so 
[91]. 
For illustration purpose, the principles of a narrative review are briefly described. For 
a narrative review we would probably include some studies included in this meta-
analysis and some of the excluded studies due to methodological reasons. We might 
practically include the following studies [93-99]. Two of them were of a single blind 
design [93, 96] and five were open-label studies [94, 95, 97-99]. The duration of the 
studies varied from 56 days to 12 months and the number of participants from eight 
to 338. Efficacy was measured with the same scores as in our meta-analysis (CMAI, 
NPI, BEHAVE-AD and BPRS) and, if multiple scores were presented, the same order 
of choice as in the meta-analysis would be applied. A result would be considered 
significant with a p-value less the 0,05 in the analysis from baseline to endpoint. The 
results of the efficacy analysis for each individual study shows nine significant 
improvements under antipsychotic treatment and two non-significant results which is 
a ratio of 9:2. A ratio of 9:2 might be tempting for the reader to suppose a great 
advantage of antipsychotic treatment compared to placebo. However, there is and 
there can be no statement of the treatment effect itself. Regarding the fact that 
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results can be highly significant but with only a marginal effect far from being 
clinically relevant, the interpretation of narrative reviews calls for a degree of caution.    
To address the intensity of treatment or side-effects meta-analyses provide effect 
sizes as results. These effects can be quantified: according to Cohen an effect size 
of 0,2 is small, 0,5 medium and 0,8 large [100].This systematic review and meta-
analysis claim to answer the question as to which antipsychotic class is superior. As 
explained above the studies included - and thus this analysis - are subject to several 
limitations. This means that all the results have to be regarded in a certain context.  
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RESULTS 
EFFICACY 
This is the first meta-analysis to compare first and second generation antipsychotics 
in the treatment of BPSD. In the pooled efficacy analysis there is a small effect 
favouring antipsychotic treatments for FGA and SGA. FGAs would seem to be 
superior. But the studies of the FGA group were older, with a smaller number of 
participants and of poorer quality. There are randomised studies (not included for 
missing placebo control) comparing SGA and FGA (haloperidol) directly [101, 102]. 
These did not find differences in efficacy or side effects with one exception: 
significant more EPS measured on the Simpson Angus Scale in patients treated with 
haloperidol [101].  
The efficacy analysis of single antipsychotics was very inhomogeneous. There were 
small to moderate effects for most of the antipsychotics, which were rarely significant. 
Treatment of BPSD with the FGAs pimozide and thioridazine proved not to be 
superior to placebo. For SGAs these results are consistent to other meta-analysis [6, 
103]. These only analysed SGAs. Davidson and co-workers only included three 
studies in their analysis [103]. Schneider differentiated in his analysis for each SGA 
between the scales (e.g. BPRS, CMAI, NPI): for most of the antipsychotics, results 
are consistent independent of the applied scale [6]. In this meta-analysis, we found 
with exception of two antipsychotics treatment effects in BPSD. These effects are 
rather small, but regarding that study patients are probably given more attention in 
general, might limit the observed treatment efficacy compared to placebo. In daily 
routine this effect might be larger as naturalistic studies suggest (see below). 
Nevertheless treatment options, especially in acute BPSD, are rare. 
Benzodiazepines can also be used but elevate the risk of fall and associated injuries 
and hospital admission [104] as well as they increase the risk of delirium in the 
elderly [105]. Another alternative could be anticonvulsants like topiramate. In a study 
by Mowla and Pani topiramate proved to have a comparable efficacy to risperidone in 
BPSD [106].  
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EFFECTIVENESS 
Effectiveness and tolerability seems to be comparable between first and second 
generation antipsychotics in this meta-analysis. The reporting of effectiveness and 
tolerability was very incomplete and highly varies between the studies (see table 2). 
Mostly older studies, commonly investigating FGA are lacking these data. But also 
younger studies suffer from under-reporting of these items. 
The global drop-outs were equal for all groups here (RR = 1,005; p = 0,833). Other 
meta-analyses confirm this finding [76, 103]. Drop-out rates due to specific reasons 
like inefficacy and adverse events have not been investigated by others so far. We 
found drop-outs due to inefficacy to be slightly higher for placebo (RR = 0,702; 
p = 0,004) and, due to adverse events to be increased for antipsychotics 
(RR = 1,537; p = 0,000). These effectiveness results indirectly mirror the efficacy and 
tolerability results of antipsychotic treatment in dementia, as inefficacy leading to an 
advanced drop-out of the study is more often detected in placebo. And as expected 
there were more severe adverse events leading to an advanced cessation for study 
participants belonging to the verum group. 
 
TOLERABILITY 
Our tolerability analysis revealed mostly no difference between FGA and SGA, but 
between antipsychotics and placebo. Under antipsychotic treatment there was less 
agitation compared to placebo (RR = 0,773; p = 0,012). Agitation can be one 
symptom of BPSD and therefore a reduction in agitation is preferable and expected 
under antipsychotic treatment.  
As agitation is reduced under antipsychotic treatment, the risk for somnolence raises 
(RR = 2,7; p < 0,001) in our pooled analysis of all antipsychotics. That result is 
consistent with former meta-analytic investigations on SGAs [6, 103]. With focus on 
FGA a non-significant elevated risk for somnolence is seen under haloperidol 
treatment (RR = 3,0; p = 0,07), which might be due to high doses. Elderly patients 
react very sensitive on antipsychotics. Doses of 0,25 mg are recommended [107]. 
The mean daily haloperidol dosage was 1,2 mg [44], 1,9 mg [47], and 3,53 mg [30] in 
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the studies included to this analysis. Estimating three to four daily doses, all studies 
used higher doses than recommended. There was only one trial investigating 
somnolence under tiapride treatment. Although it belongs to lower potency 
antipsychotics it has only a minor sedating effect. This fact is mirrored in this meta-
analysis: the risk for somnolence was equal between tiapride and placebo 
(RR = 1,01; p = 0,98).  
The risk for accidental injuries is in this meta-analysis almost the same for placebo 
and antipsychotics (RR = 0,973; p = 0,691). There is only a marginal difference 
between FGA and SGA (FGA vs. PBO: RR = 1,078; p = 0,642; SGA vs. PBO: 
RR = 0,964; p = 0,592) which is compared to placebo far from statistical significance. 
The meta-analysis by Schneider and colleagues investigating SGA confirms these 
results [6]. 
Our analysis for the risk of death under antipsychotic treatment vs. placebo treatment 
was very heterogeneous between the individual studies. It was irrelevant, if the 
antipsychotic belonged to first or second generation. The pooled individual drug 
results show a higher probability of death under antipsychotic treatment, but without 
statistical significance. In case of all trials pooled, there is an elevated risk as well 
with a statistical significance (RR = 1,564, p = 0,039). Comparing FGA vs. placebo 
and SGA vs. placebo there are only minor differences without reaching the level of 
significance (FGA vs. PBO: RR = 1,435; p = 0,784; SGA vs. PBO: RR = 1,52; 
p = 0,059). The meta-analysis entitled “Risk of death with atypical antipsychotic drug 
treatment for dementia” showed similar results [76]. The authors calculated an odds 
ratio (OR) to measure the risk of death. They found an OR of 1,54 (p = 0,02), which 
means a 1,54 times higher chance for death under antipsychotic treatment than 
under placebo. A remaining point of criticism is that for effectiveness analysis the RR 
is the more intuitive instrument.  
The occurrence of extrapyramidal symptoms did not differ statistically significant in 
our overall analysis (antipsychotics vs. placebo). Only in the parkinsonism overall 
analysis there is a trend for a higher risk for antipsychotic treatment (RR = 1,679; p = 
0,053). Analysis of the Simpson Angus Scale reveals a small effect worsening for the 
verum group (Hedges’s g = 0,201; p = 0,005). Most of the FGA studies did not 
provide data on EPS. Where provided the subgroup analysis mirrors the typical side-
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effects of e.g. Haloperidol (AIMS: Hedges’s g = 0,249; p = 0,095; SAS: Hedges’s g = 
0,825; p < 0,001). Regarding dichotomous EPS data collection there is an elevated 
risk for some FGAs compared to placebo (haloperidol: RR = 2,02; p < 0,001; 
loxapine: RR = 2,75; p = 0,04).  Another meta-analysis focussing on SGA only found 
an odds ratio of 1,51 (p = 0,0005) for extrapyramidal signs and symptoms [6]. Here 
again the odds ratio is the less intuitive and less appropriate statistical tool for 
assessing the risk of adverse events. With those data (13% EPS for SGA and 8% for 
PBO) a risk ratio of 1,625 can be calculated. We detected a risk ratio of 1,418, 
including FGA and more SGA studies. But still the results are consistent: there is an 
elevated risk for EPS under antipsychotic treatment for FGA and SGA. 
 
COGNITION 
The present analysis of cognitive abilities represented with the MMSE varied from 0 
to -2,06 (absolute values) between the included studies. Meta-analytic calculations 
revealed a trend towards deterioration under antipsychotic treatment, compared to 
placebo (fixed effects model: Hedges’s g = -0,101; p = 0,044; random effects model: 
Hedges’s g = -0,066; p = 0,343). Based on heterogeneity, the random effects model 
seems to be appropriate. The displayed negative effect is neither strong nor 
statistically significant. The meta-analysis by Schneider and co-workers resulted in a 
statistically highly significant but small effect (weighted mean difference = 0,73, 
p < 0,0001) in MMSE worsening for SGAs [6]. This work included four SGA studies 
less than we did. Their corresponding heterogeneity analysis was not statistically 
significant. So they probably used a fixed effects model. In general there was a 
strong underreporting of the MMSE at the endpoint of the study or the mean change 
in MMSE, respectively.     
It is questionable whether these negative effects on cognition are so marginal in 
clinical reality. Sakurai and co-workers found out that in patients with schizophrenia 
D2-receptor occupancy higher than 80% was associated with impairment in cognitive 
functioning and vigilance [108]. In healthy subjects there is also evidence that a 
single dose of haloperidol [109] as well as the administration of haloperidol up to 
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seven days can cause a decline in cognitive functioning [110-112], but also 
aripiprazole [112].  
In RCTs there are highly selected samples with a daily schedule and good care. A 
cognitive decline was may be minimized. In a nursing home setting the cognitive 
decline of a dementia patient taking antipsychotics could be much worse. After two 
months of treatment of BPSD with risperidone in rural nursing homes, Ellingrod found 
a cognitive decline of 2,27 (Standard Deviation 3,13) in the MMSE, which was 
significant [113]. In the olanzapine group of the same study, the loss in the MMSE 
was 1,38 (Standard Deviation 2,77). A limitation of this study is admittedly the very 
small sample size of 19 patients (eleven patients taking risperidone, eight taking 
olanzapine). A single-blind pilot study on haloperidol for treating BPSD in AD by 
Devanand shows an interesting development on the MMSE [93]. For the first four 
weeks the patients receive placebo, than haloperidol for eight weeks and then again 
placebo for four weeks. At the end of the first placebo phase the MMSE was 23,3 
(SD = 16,4). At the end of the haloperidol phase it decreased to 18,1 (SD = 15,3). At 
the end of the last placebo phase it increased to a value of 20,1 (SD = 14,4). This 
study is limited to its very small number of participants (n = 9). In direct FGA vs. SGA 
competition studies the MMSE mean change values between haloperidol (-0,15; 
SD = N/A) and risperidone (-0,42; SD = N/A) [101], or haloperidol (-0,13, SD = 3,54) 
and olanzapine (0,53, SD = 3,54) [102] differs only slightly. We can confirm these 
results in our meta-analysis. But we only included two trials investigating FGAs (both 
haloperidol) due to underreporting. The study entitled “Olanzapine does not enhance 
cognition in non-agitated and non-psychotic patients with mild to moderate 
Alzheimer’s dementia” was conducted on outpatients [96]. 178 patients were 
randomised to olanzapine and 90 to placebo. After 26 weeks the MMSE worsened by 
2.06 points (SE = 0.29; within-group p-value < 0.001) in the olanzapine group and by 
0.57 (SE = 0.38; within-group p-value = 0.139) in the placebo group. The p-value 
between both groups was 0.002. A significant worsening of cognition was also seen 
in the ADAS-Cog. 
The usage of MMSE assessing the cognitive course in dementia is questionable. 
There are more specific and sophisticated tools like e.g. ADAS-Cog. But if any 
cognitive course was reported, it was MMSE. Only very few studies assessed or 
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published ADAS-Cog additionally. Summing up, there is a treatment effect of 
antipsychotics in BPSD with considerable side-effects and serious adverse events 
like EPS or death. The observed small effect of higher cognitive decline in the 
treatment groups could be quite larger in real life. In the light of very high prescription 
rates of antipsychotics in dementia patients [114-116], current prescription manner 
has to be reconsidered. 
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LIMITATIONS AND CONCLUSION 
The summarized effect is based on the data of included randomized controlled trials. 
These trials have strict and predefined exclusion criteria. This leads to a highly 
selected sample. Usually dementia patients are treated by primary care physicians, 
whereas many RCTs include patients who only have contact to psychiatric research 
centres [117]. In addition RCTs have a predefined treatment regimen. In daily clinical 
routine there are variations of the dosage depending on the patient’s condition. 
Furthermore, patients in a study setting have a structured daily schedule, medical 
examinations and care. In a nursing home dementia patients do not often have these 
advantages. Nurses have less time per patient for care and a structured daily 
schedule is lacking. In this situation a larger benefit is described by some open label 
studies. One study took place in nursing homes [118], one in different medical 
centres [94], and two in outpatients [119, 120]. All four studies used risperidone. One 
study compared risperidone versus melperone [119]. All treatments led to an 
improvement in behavioural and psychological symptoms of dementia. In the study of 
Wancata general practitioners, care-givers and patients were asked via questionnaire 
about the efficacy of risperidone [118]. The results are impressive. According to the 
general practitioners, the efficacy is excellent in 53% of the patients and satisfactory 
in 44%. Care-givers share this view. Patients judge efficacy as excellent in 41% and 
as satisfactory in 54%. Kurz et al. also found only significant improvements in 
measured symptoms, like agitation, aggressiveness, disturbance of sleep-wake 
rhythm and others [120]. When regarding these optimistic results, the small sample 
sizes and the industrial sponsoring should not be forgotten. Nevertheless, there 
seems to be a measureable effect in treating BPSD with antipsychotics. 
Another problem we are faced with is the varying quality of studies within the 
included randomized controlled trials. Older studies are lacking certain quality 
standards. Quality-based principles and methods were established in the nineties 
with the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) [121]. The aim of Good Clinical 
Practice (GCP) recommendations issued by the ICH was to define standards for the 
ethical, scientific and technical quality on drug substances, diagnosis and therapies. 
This concerns in particular the protection of patients in clinical trials, the authenticity 
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of data obtained and results and the establishment of responsibilities associated with 
clinical drug trials [122]. 
We included in this meta-analysis 17 RCTs investigating only SGA and 8 RCTs 
investigating only FGA. The 17 RCTs on SGA included an average of 303 
participants per study, whereas the 8 RCTs on FGA included an average of 85 
participants per study. 15 SGA studies were published between 2000 and 2008, one 
in 1999 and one remains unpublished. 3 FGA studies were published in the eighties, 
one in 1998 and three between 2000 and 2002. So we assume the trials from the 
eighties and early nineties to have a different quality standard, which would not 
satisfy current standards. These are trials researching FGA only. What is also 
mentionable is the fact that mostly older FGA trials have in average considerably less 
participants than the SGA trials. They are probably lacking a power analysis. 
 
Antipsychotics are the mainstay in the treatment of BPSD, especially in an acute 
onset of symptoms. According to the present analysis, there seems to be no relevant 
difference between first and second generation antipsychotics regarding efficacy, 
tolerability and side-effects. Open-label studies suggest that efficacy is probably 
higher in daily clinical routine than in randomised controlled trials. However, the use 
of antipsychotics should be minimized to an absolute necessary, in view of the 
elevated risk of death and stroke, as well as a possible acceleration of cognitive 
decline.  
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